Evofem Biosciences (EVFM) 10-Q 14 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 11, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-36754
Entity Registrant Name	EVOFEM BIOSCIENCES, INC.
Entity Central Index Key	0001618835
Entity Tax Identification Number	20-8527075
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	7770 Regents Road
Entity Address, Address Line Two	Suite 113-618
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92122
City Area Code	(858)
Local Phone Number	550-1900
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	EVFM
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,060,209

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents		$ 2,769
Restricted cash	636	1,207
Trade accounts receivable, net	5,198	1,126
Inventories	3,674	5,379
Prepaid and other current assets	2,508	2,218
Total current assets	12,016	12,699
Property and equipment, net	1,668	3,940
Operating lease right-of-use assets	195	4,406
Other noncurrent assets	195	4,118
Total assets	14,074	25,163
Current liabilities:
Accounts payable	17,151	14,984
Convertible Notes - carried at fair value (Note 4)	15,600	39,416
Convertible Notes - Adjuvant (Note 4)	27,401	26,268
Accrued expenses	4,216	4,124
Accrued compensation	1,550	2,175
Operating lease liabilities-current	173	2,311
Derivative liabilities		1,676
Other current liabilities	3,625	2,876
Total current liabilities	69,716	93,830
Operating lease liabilities- noncurrent	22	3,133
Total liabilities	69,738	96,963
Commitments and contingencies (Note 7)
Convertible and redeemable preferred stock, $0.0001 par value
Series B-1, B-2, and C convertible preferred stock, 5,000, 5,000, and 1,700 shares authorized; no shares issued and outstanding at June 30, 2023 and December 31, 2022
Stockholders’ deficit:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2023 and December 31, 2022
Common Stock, $0.0001 par value; 500,000,000 shares authorized; 2,524,239 and 984,786 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively
Additional paid-in capital	820,587	817,367
Accumulated other comprehensive income	73,355	49,527
Accumulated deficit	(949,606)	(938,694)
Total stockholders’ deficit	(55,664)	(71,800)
Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit	$ 14,074	$ 25,163

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Convertible preferred stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Temporary equity, shares issued	0	0
Temporary equity, shares outstanding	0	0
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	2,524,239	984,786
Common stock, shares outstanding	2,524,239	984,786
Series B1 Convertible and Redeemable Preferred Stock [Member]
Temporary equity, shares authorized	5,000	5,000
Series B2 Convertible and Redeemable Preferred Stock [Member]
Temporary equity, shares authorized	5,000	5,000
Series C Convertible and Redeemable Preferred Stock [Member]
Temporary equity, shares authorized	1,700	1,700

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Product sales, net	$ 2,458	$ 6,034	$ 8,267	$ 10,285
Operating Expenses:
Cost of goods sold	2,293	1,285	3,669	2,351
Research and development	402	7,744	942	18,135
Selling and marketing	2,197	12,298	6,051	25,003
General and administrative	4,902	9,126	8,520	18,144
Total operating expenses	9,794	30,453	19,182	63,633
Loss from operations	(7,336)	(24,419)	(10,915)	(53,348)
Other income (expense):
Interest income	8	4	26	5
Other expense, net	(1,127)	(415)	(1,445)	(886)
Loss on issuance of financial instruments	(27)	(71,150)	(111)	(72,002)
Change in fair value of financial instruments	(73)	(29,980)	1,539	(31,614)
Total other income (expense), net	(1,219)	(101,541)	9	(104,497)
Loss before income tax	(8,555)	(125,960)	(10,906)	(157,845)
Income tax expense	(3)	(20)	(6)	(23)
Net loss	(8,558)	(125,980)	(10,912)	(157,868)
Convertible preferred stock deemed dividends		1,908		1,827
Net loss attributable to common stockholders	$ (8,558)	$ (124,072)	$ (10,912)	$ (156,041)
Net loss per share, basic	$ (5.43)	$ (580.48)	$ (6.60)	$ (169.73)
Net loss per share, diluted	$ (5.43)	$ (580.48)	$ (6.60)	$ (169.73)
Weighted-average shares used to compute net loss, basic	1,576,158	217,028	1,654,026	930,112
Weighted-average shares used to compute net loss, diluted	1,576,158	217,028	1,654,026	930,112

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Net loss	$ (8,558)	$ (125,980)	$ (10,912)	$ (157,868)
Other comprehensive income (loss):
Change in fair value of financial instruments attributed to credit risk change	8,368	(3,675)	23,828	(3,494)
Comprehensive income (loss)	$ (190)	$ (129,655)	$ 12,916	$ (161,362)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Convertible and Redeemable Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Common Stock [Member] Stock Purchase Agreement [Member]	Common Stock [Member] IPO [Member]	Common Stock [Member] Rights [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Rights [Member]	AOCI Attributable to Parent [Member]	AOCI Attributable to Parent [Member] Rights [Member]	Retained Earnings [Member]	Retained Earnings [Member] Rights [Member]	Total	Rights [Member]	Preferred Stock [Member] Series B Convertible and Redeemable Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible and Redeemable Preferred Stock [Member]
Balance, value at Dec. 31, 2021					$ 751,276,000		$ 5,089,000		$ (860,680,000)		$ (104,315,000)
Common stock shares outstanding at Dec. 31, 2021	86,666
Temporary equity, balance shares at Dec. 31, 2021													5,000
Temporary equity, beginning balance at Dec. 31, 2021													$ 4,740,000
Stock-based compensation					1,067,000						1,067,000
Change in fair value of financial instruments attributed to credit risk change (see Note 4)							181,000				181,000
Net loss									(31,888,000)		(31,888,000)
Issuance of common stock - Stock Purchase Agreement (see Note 8), shares	9,673
Issuance of common stock - Stock Purchase Agreement (see Note 8)					5,400,000						5,400,000
Conversion of series B-2 convertible preferred stock, shares													(650)
Conversion of series B-2 convertible preferred stock, value													$ (619,000)
Conversion of series B-2 convertible preferred stock, shares		978
Conversion of series B-2 convertible preferred stock					708,000						708,000
Exchange of series B-2 convertible preferred stock, shares													(1,700)	1,700
Exchange of series B-2 convertible preferred stock, value													$ (1,616,000)	$ 1,616,000
Exchange of series B-2 convertible preferred stock (see Note 8)
Convertible preferred stock deemed dividends, value													16,000	1,000
Convertible preferred stock deemed dividends					(81,000)						(81,000)
Restricted stock awards issued, shares		1,259
Restricted stock awards issued
Modification of the Baker Warrants (see Note 8)					828,000						828,000
Balance, value at Mar. 31, 2022					759,198,000		5,270,000		(892,568,000)		(128,100,000)
Common stock shares outstanding at Mar. 31, 2022	98,576
Temporary equity, beginning balance at Mar. 31, 2022													$ 2,521,000	$ 1,617,000
Temporary equity, shares outstanding, balance at Mar. 31, 2022													2,650	1,700
Balance, value at Dec. 31, 2021					751,276,000		5,089,000		(860,680,000)		(104,315,000)
Common stock shares outstanding at Dec. 31, 2021	86,666
Temporary equity, balance shares at Dec. 31, 2021													5,000
Temporary equity, beginning balance at Dec. 31, 2021													$ 4,740,000
Change in fair value of financial instruments attributed to credit risk change (see Note 4)											(3,494,000)
Net loss											(157,868,000)
Convertible preferred stock deemed dividends, value											(1,827,000)
Balance, value at Jun. 30, 2022					802,274,000		1,595,000		(1,019,864,000)		(215,995,000)
Common stock shares outstanding at Jun. 30, 2022	632,458
Temporary equity, beginning balance at Jun. 30, 2022
Temporary equity, shares outstanding, balance at Jun. 30, 2022
Balance, value at Mar. 31, 2022					759,198,000		5,270,000		(892,568,000)		(128,100,000)
Common stock shares outstanding at Mar. 31, 2022	98,576
Temporary equity, balance shares at Mar. 31, 2022													2,650	1,700
Temporary equity, beginning balance at Mar. 31, 2022													$ 2,521,000	$ 1,617,000
Issuance of common stock upon cash exercise of warrants					32,889,000						32,889,000
Issuance of common stock upon cash exercise of warrants, shares	327,719
Stock-based compensation					1,081,000						1,081,000
Change in fair value of financial instruments attributed to credit risk change (see Note 4)							(3,675,000)				(3,675,000)
Net loss									(125,980,000)		(125,980,000)
Issuance of common stock - Stock Purchase Agreement (see Note 8), shares	7,067
Issuance of common stock - Stock Purchase Agreement (see Note 8)					2,553,000						2,553,000
Conversion of series B-2 convertible preferred stock, shares													(550)
Conversion of series B-2 convertible preferred stock, value													(524,000)	(72,000)
Conversion of series B-2 convertible preferred stock, shares	1,369
Conversion of series B-2 convertible preferred stock					543,000						543,000
Convertible preferred stock deemed dividends, value											(1,908,000)		$ 102,000	$ 83,000
Convertible preferred stock deemed dividends
Modification of the Baker Warrants (see Note 8)					231,000						231,000
Issuance of common stock - May 2022 Public Offering (see Note 8), shares			181,320
Issuance of common stock - May 2022 Public Offering (see Note 8)					1,264,000						1,264,000
Issuance of common stock - ESPP, shares	601
Issuance of common stock - ESPP					20,000
Issuance of common stock - a360 Media, shares	18,547
Issuance of common stock - a360 Media					858,000						858,000
Cash repurchase of fractional common stock after the reverse stock split, shares	(88)
Cash repurchase of fractional common stock after the reverse stock split					(18,000)						(18,000)
May 2022 exchange transaction, shares													(2,100)	(1,700)
May 2022 exchange transaction, value													$ (2,099,000)	$ (1,628,000)
May 2022 exchange transaction, shares	(2,600)
May 2022 exchange transaction					3,655,000				(1,316,000)		2,339,000
May 2022 exchange transaction					(3,655,000)				1,316,000		(2,339,000)
Restricted stock awards cancelled, shares	(53)
Restricted stock awards cancelled
Balance, value at Jun. 30, 2022					802,274,000		1,595,000		(1,019,864,000)		(215,995,000)
Common stock shares outstanding at Jun. 30, 2022	632,458
Temporary equity, beginning balance at Jun. 30, 2022
Temporary equity, shares outstanding, balance at Jun. 30, 2022
Balance, value at Dec. 31, 2022					817,367,000		49,527,000		(938,694,000)		$ (71,800,000)
Common stock shares outstanding at Dec. 31, 2022	984,786										984,786
Temporary equity, balance shares at Dec. 31, 2022											0
Temporary equity, beginning balance at Dec. 31, 2022
Issuance of common stock upon cash exercise of warrants					67,000						67,000
Issuance of common stock upon cash exercise of warrants, shares	24,200
Issuance of common stock upon noncash exercise of purchase rights						$ 180,000						$ 180,000
Issuance of common stock upon noncash exercise of Purchase Rights, shares				718,704
Issuance of February and March 2023 Notes (See Note 4)					1,629,000						1,629,000
Stock-based compensation					417,000						417,000
Change in fair value of financial instruments attributed to credit risk change (see Note 4)							15,460,000				15,460,000
Net loss									(2,354,000)		(2,354,000)
Balance, value at Mar. 31, 2023					819,660,000		64,987,000		(941,048,000)		(56,401,000)
Common stock shares outstanding at Mar. 31, 2023	1,727,690
Balance, value at Dec. 31, 2022					817,367,000		49,527,000		(938,694,000)		$ (71,800,000)
Common stock shares outstanding at Dec. 31, 2022	984,786										984,786
Temporary equity, balance shares at Dec. 31, 2022											0
Temporary equity, beginning balance at Dec. 31, 2022
Change in fair value of financial instruments attributed to credit risk change (see Note 4)											23,828,000
Net loss											(10,912,000)
Convertible preferred stock deemed dividends, value
Balance, value at Jun. 30, 2023					820,587,000		73,355,000		(949,606,000)		$ (55,664,000)
Common stock shares outstanding at Jun. 30, 2023	2,524,239										2,524,239
Temporary equity, beginning balance at Jun. 30, 2023
Temporary equity, shares outstanding, balance at Jun. 30, 2023											0
Balance, value at Mar. 31, 2023					819,660,000		64,987,000		(941,048,000)		$ (56,401,000)
Common stock shares outstanding at Mar. 31, 2023	1,727,690
Issuance of common stock upon cash exercise of warrants					101,000						101,000
Issuance of common stock upon cash exercise of warrants, shares	122,729
Issuance of common stock upon noncash exercise of purchase rights						$ 6,000						$ 6,000
Issuance of common stock upon noncash exercise of Purchase Rights, shares				673,820
Stock-based compensation					268,000						268,000
Change in fair value of financial instruments attributed to credit risk change (see Note 4)							8,368,000				8,368,000
Net loss									(8,558,000)		(8,558,000)
Noncash reclassification of liability-classified derivatives to equity					53,000						53,000
Issuance of April 2023 Notes (See Note 4)					499,000						499,000
Conversion of series B-2 convertible preferred stock					543,000						543,000		$ (524,000)	$ (72,000)
Convertible preferred stock deemed dividends, value
Issuance of common stock - ESPP											20,000
Balance, value at Jun. 30, 2023					$ 820,587,000		$ 73,355,000		$ (949,606,000)		$ (55,664,000)
Common stock shares outstanding at Jun. 30, 2023	2,524,239										2,524,239
Temporary equity, beginning balance at Jun. 30, 2023
Temporary equity, shares outstanding, balance at Jun. 30, 2023											0

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (10,912)	$ (157,868)
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:
Loss on issuance of financial instruments	111	72,002
Change in fair value of financial instruments	(1,539)	31,614
Financial instrument modification expense		1,056
Stock-based compensation	685	2,148
Depreciation	418	515
Noncash interest expense	1,134	1,055
Noncash lease expenses	1,208	301
Net gain on lease termination	(459)
Net loss on disposal of property and equipment	1,858
Noncash instrument exchange expense		514
Changes in operating assets and liabilities:
Trade accounts receivable	(4,072)	(855)
Inventories	1,705	1,542
Prepaid and other assets	2,435	(2,749)
Accounts payable	2,167	4,728
Accrued expenses and other liabilities	840	(1,929)
Accrued compensation	(625)	816
Operating lease liabilities	(1,388)	(469)
Net cash and restricted cash used in operating activities	(6,434)	(47,579)
Cash flows from investing activities:
Purchases of property and equipment	(4)	(236)
Net cash and restricted cash used in investing activities	(4)	(236)
Cash flows from financing activities:
Proceeds from issuance of common stock - Stock Purchase Agreement		7,438
Proceeds from issuance of common stock and warrants, net of discounts, fees and commissions - Public Offerings		24,882
Proceeds from issuance of common stock - exercise of warrants	160	20,922
Proceeds from issuance of common stock - ESPP and exercise of stock options		20
Borrowings under term notes	2,138	10,000
Payments under term notes		(5,892)
Cash paid for financing costs		(859)
Cash repurchase of fractional common stock after the reverse stock split		(18)
Net cash and restricted cash provided by financing activities	2,298	56,493
Net change in cash, cash equivalents and restricted cash	(4,140)	8,678
Cash, cash equivalents and restricted cash, beginning of period	4,776	13,588
Cash, cash equivalents and restricted cash, end of period	636	22,266
Supplemental disclosure of noncash investing and financing activities:
Financing costs included in accounts payable and accrued expenses		563
Purchases of property and equipment included in accounts payable and accrued expenses		189
Conversion of Series B-2 convertible preferred stock to common stock		1,187
Exchange of series B-2 convertible preferred stock to series C convertible preferred stock		1,616
Issuance of common stock for prepaid advertising		858
Issuance of common stock upon exercise of purchase rights	$ 186

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Description of Business Evofem is a San Diego-based, commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. The Company’s first commercial product, Phexxi ® 16.8 Basis of Presentation and Principles of Consolidation The Company prepared the unaudited interim condensed consolidated financial statements included in this Quarterly Report in accordance with accounting principles generally accepted (GAAP) in the United States for interim financial information and the rules and regulations of the Securities and Exchange Commission (SEC) related to quarterly reports on Form 10-Q. The Company’s financial statements are presented on a consolidated basis, which include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements do not include all information and disclosures required by GAAP for annual audited financial statements and should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2022 included in its Annual Report on Form 10-K as filed with the SEC on April 27, 2023 (the 2022 Audited Financial Statements). The unaudited interim condensed consolidated financial statements included in this report have been prepared on the same basis as the Company’s audited consolidated financial statements and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations, cash flows, and statements of convertible and redeemable preferred stock and stockholders’ deficit for the periods presented. The results for the three and six months ended June 30, 2023 are not necessarily indicative of the results expected for the full year. The condensed consolidated balance sheet as of December 31, 2022 was derived from the 2022 Audited Financial Statements. Reverse Stock Split On March 15, 2023, the Company’s shareholders approved a reverse stock split between 1-for-20 and not more than 1-for-125 at any time on or prior to March 15, 2024. The Company determined on a ratio of 1-for-125 for the Reverse Stock Split. On May 18, 2023, the Reverse Stock Split became effective. Risks, Uncertainties and Going Concern Any disruptions in the commercialization of Phexxi and/or its supply chain could have a material adverse effect on the Company’s business, results of operations and financial condition. The condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities, in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty. The Company’s principal operations have been related to research and development, including the development of Phexxi, and to its commercially related sales and marketing efforts. Additional activities have included raising capital, identifying alternative manufacturing to lower the cost of goods sold (COGS), seeking ex-U.S. licensing partners to add non-dilutive capital to the consolidated balance sheet, and establishing and maintaining a corporate infrastructure to support a commercial product. The Company has incurred operating losses and negative cash flows from operating activities since inception. In the first half of 2023, as described in Note 4 – Debt Note 8 – Stockholders’ Deficit, 2.1 Note 4 – Debt 0.6 57.7 949.6 Effective October 3, 2022, the Company’s common stock is listed on the OTC Venture Market (the OTCQB) of the OTC Markets Group, Inc., a centralized electronic quotation service for over-the-counter securities, under the symbol “EVFM.” The OTCQB imposes, among other requirements, a minimum $ 0.01 0.01 In October 2022, the Company reported that its Phase 3 clinical trial ( EVOGUARD) In March 2023, the Company received a Notice of Event of Default and Reservation of Rights (the Notice of Default) from Baker Bros claiming that the Company has failed to maintain the required shares reserved amount per the Third Baker Amendment as defined in Note 4 – Debt 100.0 Note 4 – Debt Management’s plans to meet the Company’s cash flow needs in the next 12 months include generating recurring product revenue, restructuring its current payables, curing the event of default under its debt arrangements, and obtaining additional funding such as through the issuance of its capital stock, non-dilutive financings, or through collaborations or partnerships with other companies, including license agreements for Phexxi in foreign markets. The Company anticipates it will continue to incur net losses for the foreseeable future. According to management estimates, liquidity resources as of June 30, 2023 are not sufficient to maintain the Company’s cash flow needs for the twelve months from the date of issuance of these condensed consolidated financial statements. If the Company is not able to obtain the required funding, through a significant increase in revenue, equity or debt financings, license agreements for Phexxi in foreign markets, or other means, or is unable to obtain funding on terms favorable to the Company, or if the event of default under its existing debt arrangements is not cured or there is another event of default affecting the notes payable, there will be a material adverse effect on commercialization and development operations and the Company’s ability to execute its strategic development plan for future growth. If the Company cannot successfully raise additional funding and implement its strategic development plan, the Company may be forced to make further reductions in spending, including spending in connection with its commercialization activities, extend payment terms with suppliers, liquidate assets where possible at a potentially lower amount than as recorded in the condensed consolidated financial statements, suspend or curtail planned operations or cease operations entirely. Any of these could materially and adversely affect the Company’s liquidity, financial condition and business prospects, and the Company would not be able to continue as a going concern. The Company has concluded that these circumstances and the uncertainties associated with the Company’s ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company’s ability to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto. Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the discount rate used in estimating the fair value of the lease right - - Note 3 – Revenue Note 4 – Debt Note 6 – Fair Value of Financial Instruments Note 7 – Commitments and Contingencies Note 9 – Stock-based Compensation Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, the Chief Executive Officer of the Company, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by the Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets. The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held. The Company’s deposits were primarily held in Silicon Valley Bank prior to its closure by regulators, however, the Company was able to regain full access to all its deposits and subsequently moved these to a different financial institution. The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the United States and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers and its past collection experience. Historically, the Company has not experienced any credit losses. As of June 30, 2023 and December 31, 2022, based on the evaluation of these factors, the Company did not record an allowance for doubtful accounts. Phexxi is distributed primarily through three major distributors and a mail-order pharmacy, which receive service fees calculated as a percentage of the gross sales, and fee per units shipped, respectively. These entities are not obligated to purchase any set number of units and distribute Phexxi on demand as orders are received. For the three and six months ended June 30, 2023, the Company’s three largest customers combined made up approximately 81 84 72 71 90 81 Significant Accounting Policies There have been no changes to the significant accounting policies that were described in Note 2 – Summary of Significant Accounting Policies Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of readily available cash in checking accounts and money market funds. Restricted cash consists of cash held in monthly time deposit accounts and letters of credit, which are collateral for the Company’s credit cards and fleet leases, as described in Note 7 – Commitments and Contingencies 0.3 25.0 Note 4 – Debt 0.8 The following table provides a reconciliation of cash, cash equivalents and restricted cash, reported within the condensed consolidated statements of cash flows (in thousands): Schedule of Reconciliation of Cash and Restricted Cash 2023 2022 Six months ended June 30, 2023 2022 Cash and cash equivalents $ - $ 19,885 Restricted cash 636 1,581 Restricted cash included in other noncurrent assets - 800 Total cash, cash equivalents and restricted cash presented in the condensed consolidated statements of cash flows $ 636 $ 22,266 Net Loss Per Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented. Potentially dilutive securities excluded from the calculation of diluted net loss per share are summarized in the table below. Common shares were calculated for the convertible preferred stock and the convertible debt using the if-converted method. Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share 2023 2022 Six months ended June 30, 2023 2022 Unvested restricted common stock subject to repurchase - 1,205 Common stock to be purchased under the 2019 ESPP - 972 Options to purchase common stock 4,268 6,857 Warrants to purchase common stock 3,642,343 984,962 Purchase rights to purchase common stock 28,783,233 - Convertible debt 158,575,812 9,969 Total 191,005,656 1,003,965 Recently Adopted Accounting Pronouncements In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments - Credit Losses (ASU No. 2022-02). This is an amendment to ASU 2016-13, where it eliminates the accounting guidance for troubled debt restructuring by creditors in Subtopic 310-40, Receivables—Troubled Debt Restructurings by Creditors, while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. ASU No. 2022-02 was effective for the Company beginning January 1, 2023 since the Company adopted ASU 2016-13 on January 1, 2020. The adoption of this new standard did not have a material impact on the Company’s condensed consolidated financial statements.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	3. Revenue The Company recognizes revenue from the sale of Phexxi in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers In accordance with ASC 606, the Company recognizes revenue when its performance obligation is satisfied by transferring control of the product to a customer. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers are located in the United States and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. Payment terms typically range from 31 66 Note 2 - Summary of Significant Accounting Policies The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when the performance obligation is satisfied. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue. Phexxi is sold to customers at the wholesale acquisition cost (WAC), or in some cases at a discount to WAC. However, the Company records product revenue net of reserves for applicable variable consideration. These types of variable consideration reduce revenue and include the following: ● Distribution services fees ● Prompt pay and other discounts ● Product returns ● Chargebacks ● Rebates ● Patient support programs, including our co-pay programs An estimate for variable consideration is made with each sale and is recorded in conjunction with the revenue being recognized. To calculate the variable consideration, the Company uses the expected value method. If the estimated amount is payable to a customer, it is recorded as a reduction to accounts receivable. If the estimated amount is payable to an entity other than a customer, it is recorded as a current liability. An estimated amount of variable consideration may differ from the actual amount. At each balance sheet date, these provisions are analyzed and adjustments are made if necessary. Any adjustments made to these provisions would also affect net product revenue and earnings. In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance such as Medicaid or through private commercial insurance. To determine these estimates, the Company relies on historical sales data showing the amount of various end-user consumer types, inventory reports from the wholesale distributors and mail-order specialty pharmacy, and other relevant data reports. Because Phexxi was launched in September 2020, this historical data is limited. Due to limits on historical data, the Company has also used trend analysis, industry data and professional judgment in developing these estimates. The specific considerations that the Company uses in estimating these amounts related to variable consideration are as follows: Distribution services fees Prompt pay and other discount The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. These discounts reduce gross product revenue at the time the revenue is recognized. Chargebacks Rebates Patient support programs Product returns As of June 30, 2023 and December 31, 2022, the variable considerations discussed above were recorded in the condensed consolidated balance sheets and consisted of $ 0.1 million in each period in contra trade accounts receivable and $ 3.1 2.6

Debt

Debt	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Debt	4. Debt Convertible Notes Baker Bros. Notes On April 23, 2020, the Company entered into a Securities Purchase and Security Agreement (the Baker Bros. Purchase Agreement) with certain affiliates of Baker Bros. Advisors LP, as purchasers (the Baker Purchasers), and Baker Bros. Advisors LP, as designated agent, pursuant to which the Company agreed to issue and sell to the Baker Purchasers (i) convertible senior secured promissory notes (the Baker Notes) in an aggregate principal amount of up to $ 25.0 At the initial closing date of April 24, 2020 (the Baker Initial Closing), the Company issued and sold Baker Notes with an aggregate principal amount of $ 15.0 1,639 Following the Baker Initial Closing, the Baker Purchasers had an option to purchase from the Company up to $ 10.0 100.0 On June 5, 2020 (the Exercise Date), the Baker Purchasers exercised the Baker Purchase Rights. At the second closing date of June 9, 2020 (the Baker Second Closing), the Baker Purchasers acquired the remaining Baker Notes with an aggregate principal amount of $ 10.0 1,092 4,575 five-year The Baker Notes have a five-year three years 10.0 10.0 2.4 3.8 0.7 1.4 117,756,776 The Baker Notes are callable by the Company on 10 100 30 9,356.25 110 110 4,575 On November 20, 2021, the Company entered into the first amendment to the Baker Bros. Purchase Agreement (the First Baker Amendment), in which each Baker Purchaser had the right to convert all or any portion of the Baker Notes into common stock at a conversion price equal to the lesser of (a) $4,575 115 115 50 The First Baker Amendment also extended, effective upon the Company’s achievement of the Financing Threshold, the affirmative covenant to achieve $ 100.0 million in cumulative net sales of Phexxi by June 30, 2022 to June 30, 2023. Additionally per the First Baker Amendment, if in any equity financing closing on or prior to the date the Company has met the Financing Threshold, the Company was required to issue warrants to purchase capital stock of the Company (or other similar consideration), the Company was also required to issue to the Baker Purchasers an equivalent coverage of warrants (or other similar consideration) on the same terms as if the Baker Purchasers participated in the financing in an amount equal to the then outstanding principal of Baker Notes held by the Baker Purchasers. In satisfaction of this requirement and in connection with the closing of the May 2022 Public Offering, the Company issued warrants to purchase 582,886 shares of the Company’s common stock at an exercise price of $ 93.75 per share (the June 2022 Baker Warrants). As required by the terms of the First Baker Amendment, the June 2022 Baker Warrants have substantially the same terms as the warrants issued in the May 2022 Public Offering. Refer to Note 8 - Stockholders’ Deficit 1.625 per share with the February and March 2023 Notes issuance, reset to $ 0.8125 per share along with the April 2023 Notes issuance as discussed below, and then further reset to $ 0.40 Note 10 – Subsequent Events On March 21, 2022, the Company entered into the second amendment to the Baker Bros. Purchase Agreement (the Second Baker Amendment), pursuant to which each Baker Purchaser now has the right to convert all or any portion of the Baker Notes into Common Stock at a conversion price equal to the lesser of (a) $ 725.81 100 100 20 EVOGUARD 93.75 100.0 On September 15, 2022, the Company entered into the third amendment to the Baker Bros. Purchase Agreement (the Third Baker Amendment), pursuant to which the conversion was amended to equal to $ 26.25 two-year The Baker Notes contain various customary affirmative and negative covenants agreed to by the Company, including timely payment, in cash, of the quarterly interest payment and maintaining an active listing. On September 12, 2022, the Company received a default notice from the Baker Purchasers due to its failure of making the required payments of accrued interest for the first and second quarters of 2022 in the aggregate amount of $ 1.4 1.0 44.2 1.4 On December 19, 2022, the Company entered into the First Amendment to the Forbearance Agreement (the Amendment) effective as of December 15, 2022 (the Amendment Effective Date) to amend certain provisions of the of the Secured Creditor Forbearance Agreement dated September 15, 2022. The Amendment revises the Secured Creditor Forbearance Agreement to (i) amend the Fifth Recital Clause to clarify that the Purchasers consent to any additional indebtedness pari passu 5.0 On March 7, 2023, Baker Bros. Advisors, LP (the Designated Agent) provided a Notice of Event of Default and Reservation of Rights (the Notice of Default) relating to the Baker Bros. Purchase Agreement. The Notice of Default claims that the Company has failed to maintain the “Required Reserve Amount” as required by the Third Baker Amendment. The Designated Agent, at the direction of the Baker Purchasers, has accelerated repayment of the outstanding balance payable. As a result, approximately $ 92.7 million, representing two times the sum of the outstanding balance and all accrued and unpaid interest thereon and all other amounts due under the Baker Bros. Purchase Agreement and other documents was due and payable within three business days of receipt of the Notice of Default. In addition, the Company did not meet the $ 100.0 The Company evaluated whether any of the Embedded Features required bifurcation as a separate component of equity. The Company elected the fair value option (FVO) under ASC 825, Financial Instruments For the quarter ended June 30, 2023, using the valuation methods discussed in Note 6 - Fair Value Financial Instruments 8.2 As of June 30, 2023, the Baker Notes are recorded at fair value in the condensed consolidated balance sheet as short-term convertible notes payable with a total balance of $ 15.6 95.7 Adjuvant Notes On October 14, 2020, the Company entered into a Securities Purchase Agreement (the Adjuvant Purchase Agreement) with Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, the Adjuvant Purchasers), pursuant to which the Company sold unsecured convertible promissory notes (the Adjuvant Notes) in aggregate principal amount of $ 25.0 The Adjuvant Notes have a five-year 7.5 7.7 Interest expense for the Adjuvant Notes for the three and six months ended June 30, 2023 and 2022 consisted of the following (in thousands): Schedule of Interest Expense 2023 2022 2023 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Coupon interest $ 507 $ 523 $ 1,004 $ 1,035 Amortization of issuance costs 60 10 128 19 Total $ 567 $ 533 $ 1,132 $ 1,054 The Adjuvant Notes are convertible, subject to customary 4.99 19.99 0.0001 6,843.75 6,843.75 30 18,750 100.0 On April 4, 2022, the Company entered into the first amendment to the Adjuvant Purchase Agreement (the Adjuvant Amendment). The Adjuvant Amendment extended, effective as of the next date the Company achieved the Qualified Financing Threshold upon the closing of the May 2022 Public Offering, the affirmative covenant to achieve $ 100.0 678.49 100 100 30 18,750 100.0 The Adjuvant Notes contain various customary affirmative and negative covenants agreed to by the Company. On September 12, 2022, the Company was in default of the Adjuvant Notes due to the default with the Baker Notes under the cross-default provision. On September 15, 2022, the Company entered into a Forbearance Agreement (the Adjuvant Forbearance Agreement) with the Adjuvant Purchasers, pursuant to which the Adjuvant Purchasers agreed to forbear from exercising any of their rights and remedies during the Forbearance Period as defined in therein, but solely with respect to the specified events of default provided under the Adjuvant Forbearance Agreement. On September 15, 2022, the Company also entered into the second amendment to the Adjuvant Purchase Agreement (the Second Adjuvant Amendment), pursuant to which the conversion price per share was reduced to $ 26.25 , subject to adjustment for certain dilutive Company equity issuance adjustments for a two-year period. In addition, the Company entered into an exchange agreement, pursuant to which the Adjuvant Purchasers agreed to exchange 10 % of the outstanding amount of the Adjuvant Notes as of September 15, 2022 (or $ 2.9 million) for rights to receive 109,842 shares of common stock (the Adjuvant Purchase Rights). The number of shares for each Adjuvant Purchase Right is initially fixed, but is subject to certain customary adjustments, and, until the second anniversary of issuance, adjustments for certain dilutive Company equity issuances. Refer to Note 8 - Stockholders’ Deficit 1.625 per share with the February 2023 Notes issuance, to $ 0.8125 per share in April 2023 0.40 Note 10 – Subsequent Events The Adjuvant Notes are accounted for in accordance with authoritative guidance for convertible debt instruments and are classified as current liabilities in the condensed consolidated balance sheets. The aggregate proceeds of $ 25.0 million were initially classified as restricted cash for financial reporting purposes due to contractual stipulations that specify the types of expenses the money can be spent on and how it must be allocated. Its conversion feature was required to be bifurcated as an embedded derivative due to the fact that the Company did not have sufficient number of shares reserved upon conversion as of December 31, 2022; however, the fair value of such feature was immaterial as of December 31, 2022. As of June 30, 2023, the Company had a sufficient number of shares reserved and the conversion feature was reclassified to stockholders’ deficit in accordance with ASC 815, Derivatives and Hedging 0.6 million and $ 0.9 Note 6- Fair Value of Financial Instruments Due to the execution of the Adjuvant Forbearance and the Second Adjuvant Amendment, the Company reviewed the Adjuvant Notes in accordance with Topics ASC 470, Debt . 2.5 million upon extinguishment, included in change in fair value of financial instruments within the condensed consolidated statements of operations for the third quarter of 2022. As discussed above, the Baker Notes’ default resulted in a cross default under all outstanding debt. As of June 30, 2023, the Adjuvant Notes are recorded in the condensed consolidated balance sheet as short-term convertible notes payable with a total balance of $ 27.4 22.4 5.0 As of June 30, 2023, and assuming the current conversion price of $ 0.8125 33,723,393 Term Notes January and March 2022 Notes On January 13, 2022, the Company entered into a Securities Purchase Agreement (the January 2022 Purchase Agreement) with institutional investors (the January 2022 Purchasers) pursuant to which the Company agreed to sell in a registered direct offering (i) unsecured 5.0 5.9 0.9 8,003 0.0001 735.00 five-year On March 1, 2022, the Company entered into a Securities Purchase Agreement (the March 2022 Purchase Agreement) with institutional investors (the March 2022 Purchasers) pursuant to which the Company agreed to sell in a registered direct offering (i) unsecured 5.0 7.45 2.45 8,303 0.0001 897.56 five-year The January and March 2022 Notes carried an interest rate of 5 18 25 Pursuant to the terms of the January and March 2022 Purchase Agreements, the Company agreed to certain restrictions on effecting variable rate transactions so long as the January and March 2022 Notes were outstanding. Also, pursuant to the terms of the January and March 2022 Purchase Agreements, the January and March 2022 Purchasers had certain rights to participate in subsequent issuances of the Company’s securities, subject to certain exceptions. On May 4, 2022, the January and March 2022 Notes were exchanged pursuant to the May 2022 Exchange, as defined below. May 2022 Notes On May 4, 2022, the Company entered into amendment and exchange agreements (the May 2022 Exchange) with the holder of issued and outstanding Series B-2 and C Preferred Stock, Seven Knots, and the January and March 2022 Notes Purchasers (collectively, the May 2022 Notes Purchasers), pursuant to which they agreed to exchange all of the January and March 2022 Notes, 2,100 1,700 4,266 5.0 22.3 1,666 6,666 309.56 five-year 2,100 1,700 4,266 The May 2022 Notes are substantially similar to the January and March 2022 Notes except that (i) the maturity date of the May 2022 Notes was August 1, 2022 and (ii) the holders of the May 2022 Notes may require the Company to redeem or exchange up to 100 20 The May 2022 Public Offering qualified as the Qualified Underwritten Offering and, in connection with the May 2022 Public Offering, the holders of the May 2022 Notes waived certain of their preemptive and redemption rights and the Company redeemed $ 5.9 The May 2022 Notes contain various customary affirmative and negative covenants to which the Company agreed. The May 2022 Notes also include other customary events of default, which include the suspension of trading of shares of the Company’s common stock on the NASDAQ Capital Market for a period of more than five 18 125 On September 15, 2022, the Company entered into exchange agreements with each of the May 2022 Notes Purchasers (the May 2022 Notes Exchange Agreements), pursuant to which the May 2022 Notes Purchasers agreed to exchange all outstanding balance of the May Notes as of September 15, 2022 using the higher interest rate and redemption premium aforementioned for purchase rights (the May Note Purchase Rights) to receive 832,237 Note 8 - Stockholders’ Deficit The Company evaluated the May 2022 Notes and determined that in accordance with ASC 470 the notes should be accounted for as a modification of the January and March 2022 Notes. The Company further evaluated the May 2022 Notes to determine if any embedded components qualified as a derivative requiring bifurcation in accordance with ASC 815. The Company determined that the embedded put options and interest rate increase feature would all require bifurcation and separate accounting. Therefore, the Company elected to use the fair value option under ASC 825 for the May 2022 Notes inclusive of the embedded features. The Company evaluated the May 2022 Warrants and determined that, in accordance with ASC 815, the warrants should be recorded at fair value and classified as a derivative liability in the condensed consolidated balance sheet. Both the May 2022 Notes and Warrants are marked-to-market at each reporting date before the exchange as described above. December 2022 Notes On December 20, 2022, the Company entered into a Securities Purchase Agreement (the December 2022 Purchase Agreement), with certain investors (the December 2022 Notes Purchasers) pursuant to which the Company agreed to sell in a registered direct offering (i) unsecured 8.0 2.3 0.8 369,230 0.0001 70 1.25 6.25 6.25 The December 2022 Notes interest rate is subject to increase to 12 % upon an event of default and these Notes have no Company right to prepayment prior to maturity; however, the Company can redeem the respective Notes at a redemption premium of 32.5 %. The December 2022 Notes Purchasers can also require the Company to redeem their notes at the respective premium rate tied to the occurrence of certain subsequent transactions, as well as require the Company to redeem the December 2022 Notes in the event of subsequent placements (as defined). Also, pursuant to the terms of the December 2022 Purchase Agreement, the December 2022 Notes Purchasers have certain rights to participate in subsequent issuances of the Company’s securities, subject to certain exceptions. Additionally, the December 2022 Notes conversion rate and warrant strike price are subject to adjustment upon the issuance of other securities (as defined) less than the stated conversion rate and strike price of $ 6.25 . The strike price adjusted to $ 1.625 as of March 31, 2023, to $ 0.8125 in April 2023 0.40 Note 10 – Subsequent Events The Company evaluated the December 2022 Notes and December 2022 Warrants, in accordance with ASC 480, Distinguishing Liabilities from Equity 0.2 February and March 2023 Notes On February 17, March 13 and March 20, 2023, the Company entered into securities purchase agreements with certain investors providing for the sale and issuance of senior subordinate convertible notes (collectively, the February and March 2023 SPAs). The February and March 2023 SPAs included (i) convertible promissory notes with aggregate original principal amounts of approximately $ 1.4 0.6 0.5 553,846 240,000 215,384 0.9 0.4 0.3 99,692 43,200 April 2023 Notes In April 2023, the Company entered into a securities purchase agreement with certain investors providing for the sale and issuance of senior subordinate convertible notes (the April 2023 SPA). The April 2023 SPA included (i) convertible promissory notes with aggregate original principal amounts of approximately $ 0.8 615,384 0.5 Upon the April 2023 Closing, the conversion and strike prices, as applicable, of the Baker Notes, Baker Warrants, May 2022 Common Warrants, June 2022 Baker Warrants, Adjuvant Notes, December 2022 Notes and Warrants, and the Notes and Warrants in the February and March 2023 Closings reset to $ 0.8125 Note 10 – Subsequent Events 0.40

Balance Sheet Details

Balance Sheet Details	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Details	5. Balance Sheet Details Inventories Inventories consist of the following (in thousands) for the period indicated: Schedule of Inventories June 30, 2023 December 31, 2022 As of June 30, 2023 December 31, 2022 Raw Materials $ 740 $ 758 Work in process (1) 1,705 4,142 Finished Goods 1,388 1,748 Total (2) $ 3,833 $ 6,648 (1) The work in process balance represents all production costs incurred for partially completed goods. (2) A portion of the total inventory balance which relates to inventory not expected to be sold within one year from the balance sheet date is included in other noncurrent assets. At June 30, 2023 and December 31, 2022, inventory included in other noncurrent assets was $ 0.2 1.3 Prepaid and Other Current Assets Prepaid and other current assets consist of the following (in thousands): Schedule of Prepaid and Other Current Assets June 30, 2023 December 31, 2022 As of June 30, 2023 December 31, 2022 Insurance $ 1,764 $ 1,387 Selling and marketing related costs - 44 Manufacturing related costs 77 82 Other 667 705 Total $ 2,508 $ 2,218 Property and Equipment, Net Property and equipment, net, consists of the following (in thousands): Schedule of Property and Equipment net Useful Life June 30, 2023 December 31, 2022 As of Useful Life June 30, 2023 December 31, 2022 Research equipment 5 years $ 653 $ 653 Computer equipment and software 3 years 648 639 Office furniture 5 years - 881 Leasehold improvements 5 years - 3,388 Construction in-process - 1,562 1,568 Property and equipment gross 2,863 7,129 Less: accumulated depreciation (1,195 ) (3,189 ) Total, net $ 1,668 $ 3,940 Depreciation and amortization expense for property and equipment is disclosed in the condensed consolidated statements of cash flows. Accrued Expenses Accrued expenses consist of the following (in thousands): Schedule of Accrued Expenses June 30, 2023 December 31, 2022 As of June 30, 2023 December 31, 2022 Clinical trial related costs $ 2,498 $ 2,574 Selling and marketing related costs 920 674 Other 798 876 Total $ 4,216 $ 4,124

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	6. Fair Value of Financial Instruments Fair Value of Financial Assets The fair values of the Company’s assets, including the money market funds, investments in marketable fixed income debt securities classified as cash and cash equivalents, and restricted cash measured on a recurring basis as of June 30, 2023 and December 31, 2022, respectively, are summarized in the following tables (in thousands): Schedule of Fair Value of Financial Assets As of June 30, 2023 December 31, 2022 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (level 2) Significant Unobservable Inputs (Level 3) Significant Unobservable Inputs (Level 3) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (level 2) Significant Unobservable Inputs (Level 3) Significant Unobservable Inputs (Level 3) Total Money market funds (1) $ - $ - $ - $ - $ - $ 2,612 $ - $ - $ - $ 2,612 Total assets $ - $ - $ - $ - $ - $ 2,612 $ - $ - $ - $ 2,612 (1) Included as a component of cash and cash equivalents and restricted cash on the accompanying condensed consolidated balance sheet. Fair Value of Financial Liabilities The following tables summarize the Company’s convertible debt instruments as of June 30, 2023 and December 31, 2022, respectively (in thousands): Schedule of Fair Value of Financial Liabilities Fair Value As of June 30, 2023 Principal Amount Unamortized Issuance Costs Accrued Interest Net Carrying Amount Amount Leveling Baker Notes (1)(2) $ 95,677 $ - $ - $ 95,677 $ 15,600 Level 3 Adjuvant Notes (3)(4) 22,500 (123 ) 5,023 27,400 - N/A December 2022 Notes (1) 2,391 - - 2,391 - Level 3 February and March 2023 Notes (1) 2,590 - - 2,590 - Level 3 April 2023 Notes (1) 784 - - 784 - Level 3 Fair Value As of December 31, 2022 Principal Amount Unamortized Issuance Costs Accrued Interest Redemption Amount Amount Exchanged Net Carrying Amount Amount Leveling Baker Notes (1)(2) $ 45,528 $ - $ - $ - $ - $ 45,528 $ 39,260 Level 3 Adjuvant Notes (3)(4) 22,500 (252 ) 4,020 - - 26,268 - N/A May 2022 Notes (1) 16,376 - 1,101 4,369 (21,846 ) - - N/A December 2022 Notes (1) 2,308 - - - - 2,308 156 Level 3 (1) These liabilities are/were carried at fair value in the condensed consolidated balance sheets. As such, the principal and accrued interest was included in the determination of fair value. The related debt issuance costs were expensed. (2) The Baker Notes principal amount includes $ 9.5 5.6 (3) The Adjuvant Notes are recorded in the condensed consolidated balance sheets at their net carrying amount which includes principal and accrued interest, net of unamortized issuance costs. (4) The principal amount and accrued interest of the Adjuvant Notes are net of the 10 2.5 0.4 The following tables summarize the Company’s derivative liabilities as of June 30, 2023 and December 31, 2022 as discussed in Note 8 - Stockholders’ Deficit (in thousands): Schedule of Fair Value of Financial Liabilities Fair Value June 30, 2023 (2) December 31, 2022 (1) Leveling April and June 2020 Baker Warrants $ N/A $ 1 Level 3 May 2022 Public Offering Warrants N/A 303 Level 3 June 2022 Baker Warrants N/A 170 Level 3 December 2022 Warrants N/A 107 Level 3 February and March 2023 Warrants N/A - Level 3 Purchase rights N/A 1,095 Level 3 Total Derivative Liabilities $ - $ 1,676 (1) As of December 31, 2022, all warrants issued by the Company are subject to liability accounting due to potential settlement in cash, an insufficient number of authorized shares and other adjustment mechanics. However, warrants with an exercise price greater than $ 2.50 de minimus (2) Upon the effectuation of the reverse split on May 18, 2023, the Company has sufficient number of authorized shares. As a result, as of June 30, 2023, all derivatives in the table above were marked-to-market with an immaterial amount on May 18, 2023, and then reclassified to equity. Change in Fair Value of Level 3 Financial Liabilities The following tables summarize the changes in Level 3 financial liabilities related to Term Notes, Baker Notes and December 2022 Notes, and February, March and April 2023 Notes measured at fair value on a recurring basis for the three and six months ended June 30, 2023 (in thousands). Schedule of Change in Fair Value of Level 3 Financial Liabilities Baker First Closing Notes Baker Second Closing Notes December 2022 Notes February and March 2023 Notes April 2023 Notes Total Balance at March 31, 2023 $ 14,280 $ 9,520 $ 3 $ 4 $ - $ 23,807 Balance at issuance - - - - 1 1 Change in fair value presented in the Condensed Consolidated Statements of Operations - - 153 7 - 160 Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Operations (4,920 ) (3,280 ) (156 ) (11 ) (1 ) (8,368 ) May 2022 exchange transaction Reclassified to equity Balance at June 30, 2023 $ 9,360 $ 6,240 $ - $ - $ - $ 15,600 Baker First Closing Notes Baker Second Closing Notes December 2022 Notes February and March 2023 Notes April 2023 Notes Total Balance at December 31, 2022 $ 23,556 $ 15,704 $ 156 $ - $ - $ 39,416 Balance at issuance - - - 11 1 12 Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Operations (14,196 ) (9,464 ) (156 ) (11 ) (1 ) (23,828 ) Balance at June 30, 2023 $ 9,360 $ 6,240 $ - $ - $ - $ 15,600 The following tables summarize the changes in Level 3 financial liabilities related to the January 2022 Notes, the March 2022 Notes, the May 2022 Notes, and the Baker Notes measured at fair value on a recurring basis for the three and six months ended June 30, 2022 (in thousands): Term Notes - January 2022 Notes Term Notes - March 2022 Notes Term Notes - May 2022 Notes Term Notes Total Baker First Closing Notes Baker Second Closing Notes Baker Notes Total Balance at March 31, 2022 $ 118 $ 149 $ - $ 267 $ 51,653 $ 34,436 $ 86,089 Balance at issuance - - 447 447 - - - Debt repayment - - (5,892 ) (5,892 ) - - - Change in fair value presented in the Condensed Consolidated Statements of Operations 2 2 9,499 9,503 (1,543 ) (1,029 ) (2,572 ) Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Operations - - - - 2,205 1,470 3,675 May 2022 exchange transaction (120 ) (151 ) - (271 ) - - - Balance at June 30, 2022 $ - $ - $ 4,054 $ 4,054 $ 52,315 $ 34,877 $ 87,192 Term Notes - January 2022 Notes Term Notes - March 2022 Notes Term Notes - May 2022 Notes Term Notes Total Baker First Closing Notes Baker Second Closing Notes Baker Notes Total Balance at December 31, 2021 $ - $ - $ - $ - $ 49,030 $ 32,687 $ 81,717 Balance at issuance 116 149 447 712 — — - Debt repayment — — (5,892 ) (5,892 ) — — - Change in fair value presented in the Condensed Consolidated Statements of Operations 4 2 9,499 9,505 1,189 792 1,981 Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Operations — — — - 2,096 1,398 3,494 May 2022 exchange transaction (120 ) (151 ) — (271 ) — — - Balance at June 30, 2022 $ - $ - $ 4,054 $ 4,054 $ 52,315 $ 34,877 $ 87,192 The following tables summarize the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three and six months ended June 30, 2023 (in thousands): May 2022 Public Offering Common Warrants June December 2022 Warrants February and March 2023 Warrants Purchase Rights Derivative Liabilities Total Balance at March 31, 2023 $ 6 $ 3 $ 1 $ 6 $ 106 $ 122 Balance at issuance - - - - 26 26 Exercises (1 ) - - - (6 ) (7 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (4 ) (2 ) (1 ) (4 ) (73 ) (84 ) Reclassified to equity (1 ) (1 ) - (2 ) (53 ) (57 ) Balance at June 30, 2023 $ - $ - $ - $ - $ - $ - April and June 2020 Baker Warrants May 2022 Public Offering Common Warrants June December 2022 Warrants February and March 2023 Warrants Purchase Rights Derivative Liabilities Total Balance at December 31, 2022 $ 1 $ 303 $ 170 $ 107 $ - $ 1,095 $ 1,676 Balance at issuance - - - - 6 105 111 Exercises - (7 ) - - - (186 ) (193 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (1 ) (295 ) (169 ) (107 ) (6 ) (961 ) (1,539 ) Reclassified to equity - (1 ) (1 ) - - (53 ) (55 ) Balance at June 30, 2023 $ - $ - $ - $ - $ - $ - $ - The following tables summarize the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three and six months ended June 30, 2022 (in thousands): Derivative Liability - Convertible Preferred Stock Conversion Feature Derivative Liability - January 2022 Warrants Derivative Liability - March 2022 Warrants Derivative Liability - May 2022 Warrants May 2022 Public Offering Common Warrants May 2022 Public Offering Pre-Funded Warrants June 2022 Baker Warrants Derivative Liabilities Total Balance at March 31, 2022 $ 92 $ 3,857 $ 3,893 $ - $ - $ - $ - $ 7,842 Balance at issuance - - - 1,613 18,034 4,633 70,238 94,518 Warrant exercises - - - - (7,145 ) (4,633 ) - (11,778 ) Change in fair value presented in the Condensed Consolidated Statements of Operations - (3,168 ) (3,210 ) (926 ) 30,352 - - 23,048 Conversion of series B-2 convertible preferred stock (19 ) - - - - - - (19 ) May 2022 exchange transaction (73 ) - - - - - - (73 ) Balance at June 30, 2022 $ - $ 689 $ 683 $ 687 $ 41,241 $ - $ 70,238 $ 113,538 Derivative Liability - Convertible Preferred Stock Conversion Feature Derivative Liability - January 2022 Warrants Derivative Liability - March 2022 Warrants Derivative Liability - May 2022 Warrants May 2022 Public Offering Common Warrants May 2022 Public Offering Pre-Funded Warrants June 2022 Baker Warrants Derivative Liabilities Total Balance at December 31, 2021 $ 202 $ - $ - $ - $ - $ - $ - $ 202 Balance at issuance - 4,562 6,025 1,613 18,034 4,633 70,238 105,105 Warrant exercises - - - - (7,145 ) (4,633 ) - (11,778 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (83 ) (3,873 ) (5,342 ) (926 ) 30,352 - - 20,128 Conversion of series B-2 convertible preferred stock (46 ) - - - - - - (46 ) May 2022 exchange transaction (73 ) - - - - - - (73 ) Balance at June 30, 2022 $ - $ 689 $ 683 $ 687 $ 41,241 $ - $ 70,238 $ 113,538 Valuation Methodology Through June 30, 2022, the fair value of the Baker Notes issued, and the change in fair value of the Baker Notes at the reporting date, were determined using a Monte Carlo simulation-based model. The Monte Carlo simulation was used to take into account several embedded features and factors, including the future value of our common stock, a potential change of control event, the probability of meeting certain debt covenants, the maturity term of the Baker Notes, the probability of an event of voluntary conversion of the Baker Notes, the probability of the failure to meet the affirmative covenant to achieve $ 100.0 The fair value of the Baker Notes is subject to uncertainty due to the assumptions that are used in the Monte Carlo simulation-based model. These factors include but are not limited to the future value of the Company’s common stock, the probability and timing of a potential change of control event, the probability of meeting certain debt covenants, the probability of an event of voluntary conversion of the Baker Notes, exercise of the put right, and exercise of the Company’s call right. The fair value of the Baker Notes is sensitive to these estimated inputs made by management that are used in the calculation. Since the third quarter of 2022, the fair value of the Baker Notes issued as described in Note 4 - Debt 3.5 19.0 January and March 2022 Notes The fair value of the January and March 2022 Notes issued as described in Note 4 - Debt May 2022 Notes The fair value of the May 2022 Notes issued as described in Note 4 - Debt December 2022 Notes and February, March and April 2023 Notes The fair value of the December 2022 Notes and February, March and April 2023 Notes issued as described in Note 4 – Debt , Purchase Rights The Adjuvant Purchase Rights and the May Note Purchase Rights (collectively the Purchase Rights) contain certain provisions that are outside the Company’s control under which the holders can force settlement in cash; as such, the Purchase Rights are recorded as derivative liabilities in the condensed consolidated balance sheets. The Purchase Rights are valued using an option pricing model (OPM), like a Black-Scholes Methodology with changes in the fair value being recorded in the condensed consolidated statements of operations. The assumptions used in the OPM are considered level 3 assumptions and include, but are not limited to, the market value of invested capital, the cumulative equity value of the Company as a proxy for the exercise price and the expected term the Purchase Rights will be held prior to exercise and a risk-free interest rate. Warrants The warrants contain certain provisions, which are outside the Company’s control, under which the holders can force settlement in cash. As such, the warrants were recorded as derivative liabilities in the condensed consolidated balance sheet as of December 31, 2022. In accordance with ASC 815 ,

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Operating Leases Fleet Lease In December 2019, the Company and Enterprise FM Trust (the Lessor) entered into a Master Equity Lease Agreement whereby the Company leases vehicles to be delivered by the Lessor from time to time with various monthly costs depending on whether the vehicles are delivered for a term of 24 36 21 0.3 Leases 12 24 2020 Lease and the First Amendment On October 3, 2019, the Company entered into an office lease for approximately 24,474 five years 0.75 On April 14, 2020, the Company entered into the first amendment to the 2020 Lease for an additional 8,816 0.05 0.8 On March 20 2023, the Company received a notice of default from its landlord for failing to timely pay March 2023 rent, resulting in a breach under the agreement. As a result, the Company’s letter of credit in the amount of $ 0.8 3.3 4.2 0.2 2022 Sublease On May 27, 2022, the Company entered into a sublease agreement with AMN Healthcare, Inc. (AMN), pursuant to which the Company agreed to sublease 16,637 0.1 3.5 0.3 Supplemental Financial Statement Information Schedule of Lease Cost Three Months Ended June 30, Six Months Ended June 30, Lease Cost (in thousands) Classification 2023 2022 2023 2022 Operating lease expense Research and development $ 59 $ 85 $ 125 $ 171 Operating lease expense Selling and marketing 88 268 247 499 Operating lease expense General and administrative 103 250 334 509 Total $ 250 $ 603 $ 706 $ 1,179 Schedule of Lease Term and Discount Rate Lease Term and Discount Rate June 30, 2023 December 31, 2022 Weighted Average Remaining Lease Term (in years) 1.17 2.68 Weighted Average Discount Rate 12 % 12 % Schedule of Operating Lease Maturities Maturity of Operating Lease Liabilities (in thousands) June 30, 2023 Remainder of 2023 (6 months) $ 94 Year ending December 31, 2024 109 Year ending December 31, 2025 9 Total lease payments 212 Less imputed interest (17 ) Total $ 195 Schedule of Supplement Cash Outflows in Operating Leases Other information (in thousands) 2023 2022 Six Months Ended June 30, Other information (in thousands) 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows in operating leases $ 1,427 $ 1,289 Other Contractual Commitments In November 2019, the Company entered into a supply and manufacturing agreement with a third party to manufacture Phexxi, with potential to manufacture other product candidates in accordance with all applicable current good manufacturing practice regulations, pursuant to which the Company has certain minimum purchase commitments based on the forecasted product sales. There were no Contingencies From time to time the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. During the six months ended June 30, 2023, the Company settled a portion of its trade payables with numerous vendors, which resulted in a $ 1.3 98 In April 2023, the Company received a Paragraph IV certification notice letter (the “Padagis Notice Letter”) regarding an Abbreviated New Drug Application (“ANDA”) submitted to the FDA by Padagis Israel Pharmaceuticals Inc. (“Padagis”). The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of Phexxi ® under 21 U.S.C. § 355(j) prior to the expiration of listed in the FDA’s Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations . On June 1, 2023, the Company filed a complaint for patent infringement in Evofem Biosciences, Inc. et al. et al. et al et al On August 7, 2023, Padagis filed its Answer and Defenses to Complaint for Patent Infringement and Defendant’s Counterclaims (the “Counterclaim”). In the Counterclaim, Padagis is seeking for the Court to dismiss the Complaint, declare the Patents-in-Suit invalid, a declaration that the filing of Padagis’ ANDA or the manufacture, use, sale, offer for sale or importation of Padagis’ Proposed Product has not, does not and would not infringe any valid claim, if any, of the Patents-in-Suit. Padagis is not seeking monetary damages in its Counterclaim. Intellectual Property Rights In 2014, the Company entered into an amended and restated license agreement (the Rush License Agreement) with Rush University Medical Center (Rush University) pursuant to which Rush University granted the Company an exclusive, worldwide license of certain patents and know-how related to its multipurpose vaginal pH modulator technology. For the U.S. patent that the Company licensed from Rush University, three Orders Granting Interim Extension (OGIEs) were received from the USPTO, extending the expiration of this patent to September 2023. Pursuant to the Rush License Agreement, the Company is obligated to pay Rush University an earned royalty based upon a percentage of net sales in the range of mid-single digits until the expiration of this patent. In September 2020, the Company entered into the first amendment to the Rush License Agreement, pursuant to which the Company is also obligated to pay a minimum annual royalty amount of $ 0.1 0.1 0.2 0.3 0.2 0.5 0.7 0.6

Stockholders_ Deficit

Stockholders’ Deficit	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders’ Deficit	8. Stockholders’ Deficit Warrants In April and June 2020, pursuant to the Baker Bros. Purchase Agreement, as discussed in Note 4 – Debt 2,732 shares of common stock in a private placement at an exercise price of $ 4,575 per share. The Second Baker Amendment provides that the exercise price of the Baker Warrants will equal the conversion price of the Baker Notes. The exercise price of the Baker warrants was reset to $ 1.625 per share in the first quarter of 2023, to $ 0.8125 per share in April 2023, and to $ 0.40 In January 2022, pursuant to the January 2022 Securities Purchase Agreement as discussed in Note 4 – Debt 8,003 735 Note 4 – Debt 8,303 897.56 In May 2022, pursuant to the exchange agreement as described in Note 4 – Debt 6,666 309.56 five-year In May 2022, pursuant to the May 2022 Public Offering as described below, the Company issued common warrants to purchase up to 568,000 shares of common stock at an exercise price of $ 93.75 per share, and pre-funded warrants to purchase up to 102,680 shares of common stock at an exercise price of $ 0.125 per share. The warrants have a five-year term and were exercisable beginning May 24, 2022. The common warrants contain (and the pre-funded warrants contained) customary 4.99 % and 19.99 % limitations on exercise provisions. The exercise price and number of shares issuable upon exercise of the common warrants is subject to adjustment for certain dilutive issuances, stock splits and similar recapitalization transactions. During the second quarter of 2022, all pre-funded warrants were exercised for an immaterial amount of cash and 225,039 shares of common warrants were exercised for total proceeds of $ 21.1 million. In June 2022, as required by the Second Baker Amendment, the Company issued the June 2022 Baker Warrants to purchase up to 582,886 0.0001 93.75 five-year 4.99 19.99 1.625 0.8125 0.40 In February, March and April 2023, pursuant to the 2023 Securities Purchase Agreement as discussed in Note 4 – Debt 1,152,122 shares of the Company’s common stock at an exercise price of $ 2.50 per share, and up to 615,384 1.25 0.8125 reset to $ 0.40 As of June 30, 2023, warrants to purchase up to 3,642,343 14.64 , Schedule of Warrants Type of Warrants Underlying Common Stock to be Purchased Exercise Price Issue Date Exercise Period Common Warrants 4 $ 6,918.75 June 11, 2014 June 11, 2014 to June 11, 2024 Common Warrants 452 $ 14,062.50 May 24, 2018 May 24, 2018 to May 24 2025 Common Warrants - $ 14,062.50 June 26, 2018 June 26, 2018 to June 26, 2025 Common Warrants 888 $ 11,962.50 April 11, 2019 October 11, 2019 to April 11, 2026 Common Warrants 1,480 $ 11,962.50 June 10, 2019 December 10, 2019 to June 10, 2026 Common Warrants 1,639 $ 0.8125 April 24, 2020 April 24, 2020 to April 24, 2025 Common Warrants 1,092 $ 0.8125 June 9, 2020 June 9, 2020 to June 9, 2025 Common Warrants 8,003 $ 735.00 January 13, 2022 March 1, 2022 to March 1, 2027 Common Warrants 8,303 $ 897.56 March 1, 2022 March 1, 2022 to March 1, 2027 Common Warrants 6,666 $ 309.56 May 4, 2022 May 4, 2022 to May 4, 2027 Common Warrants 894,194 $ 0.8125 May 24, 2022 May 24, 2022 to May 24, 2027 Common Warrants 582,886 $ 0.8125 June 28, 2022 May 24, 2022 to June 28, 2027 Common Warrants 369,230 $ 0.8125 December 21, 2022 December 21, 2022 to December 21, 2027 Common Warrants 653,538 $ 0.8125 February 17, 2023 February 17, 2023 to February 17, 2028 Common Warrants 240,000 $ 0.8125 March 13, 2023 March 13, 2023 to March 13, 2028 Common Warrants 258,584 $ 0.8125 March 20, 2023 March 20, 2023 to March 20, 2028 Common Warrants 615,384 $ 1.25 April 5, 2023 April 5, 2023 to April 5, 2028 Total 3,642,343 Convertible and Redeemable Preferred Stock In October 2021, the Company issued 5,000 0.0001 1,000.00 5,000 0.0001 1,000.00 The Series B-1 and B-2 Convertible Preferred Stock were convertible into shares of common stock at any time at a conversion price per share of the greater of Fixed Conversion Price or Variable Conversion Price as defined. All 5,000 shares of B-1 Convertible Preferred Stock were converted in 2021. Pursuant to the terms of the Series B-2 Convertible Preferred Stock, the Fixed Conversion Price was adjusted during the first quarter of 2022 for certain dilutive issuances. The adjustment period ended on April 25, 2022 and the Fixed Conversion Price was fixed at $ 332.50 from the sale of common stock pursuant to the Seven Knots Purchase Agreement. During March and April 2022, Keystone Capital converted their 1,200 shares of B-2 Convertible Preferred Stock into 2,347 shares of the Company’s common stock at a conversion price of $ 587.50 On March 24, 2022, the Company, entered into an exchange agreement with the holder of its Series B-2 Convertible Preferred Stock, pursuant to which the holder agreed to exchange 1,700 1,700 0.0001 1,000.00 On May 4, 2022, pursuant to the May 2022 Exchange, the remaining 2,100 1,700 4.8 6,666 Effective December 15, 2021, the Company amended and restated its certificate of incorporation, under which the Company is currently authorized to issue up to 5,000,000 0.0001 Nonconvertible and Redeemable Preferred Stock On December 16, 2022, the Company filed a Certificate of Designation of Series D Non-Convertible Preferred Stock, par value $ 0.0001 per share (the Series D Preferred Shares). An aggregate of 70 shares was authorized; these shares were not convertible into shares of common stock, had limited voting rights equal to 1 % of the total voting power of the then-outstanding shares of common stock entitled to vote, were not entitled to dividends, and were required to be redeemed by the Company once its shareholders approved a reverse split, as described in the Certificate of Designation. All 70 shares of the Series D Preferred were subsequently issued in connection with the December 2022 Securities Purchase Agreement as discussed in Note 5 - Debt Common Stock Effective December 15, 2021, the Company further amended its amended and restated certificate of incorporation to increase the number of authorized shares of common stock to 500,000,000 Public Offerings In May 2022, the Company completed an underwritten public offering (the May 2022 Public Offering), whereby the Company issued 181,320 shares of common stock and common warrants (the May Common Stock Warrants) to purchase 362,640 shares of common stock at a price to the public of $ 93.75 . The common warrants have an exercise price of $ 93.75 per share, a five-year term, and were exercisable beginning on May 24, 2022. In the May 2022 Public Offering the Company also issued pre-funded warrants to purchase 102,680 shares of common stock and common warrants to purchase 205,360 shares of common stock at a price to the public of $ 93.63 . The pre-funded warrants had an exercise price of $ 0.125 per share, were exercisable beginning on May 24, 2022, and were fully exercised after completion of this offering. The Company received proceeds from the May 2022 Public Offering of $ 18.1 million, net of $ 5.9 million debt repayment, underwriting discounts and offering expenses. As discussed above in Warrants 1.625 during the first quarter of 2023, to $ 0.8125 in April 2023 and with a further strike price reset to $ 0.40 Note 10 – Subsequent Events Common Stock Purchase Agreement On February 15, 2022, the Company entered into a common stock purchase agreement (the Stock Purchase Agreement) with Seven Knots, LLC (Seven Knots), pursuant to which Seven Knots agreed to purchase from the Company up to $ 50.0 1,025 8,648 675.00 Sales of common stock to Seven Knots were subject to customary 4.99 19.99 50.0 Effective May 18, 2022, the Company and Seven Knots elected to terminate the Stock Purchase Agreement without any penalty or additional cost to the Company. Purchase Rights On September 15, 2022, the Company entered into certain exchange agreements with the Adjuvant Purchasers and the May 2022 Notes Purchasers to exchange, upon request, the Purchase Rights for an aggregate of 942,080 Note 6 - Fair Value of Financial Instruments 15,218,227 673,820 28,783,233 Unregistered shares On June 8, 2022, the Company entered into an agreement for services with a360 Media, LLC (a360 Media), pursuant to which a360 Media will provide professional media support and advertising services in exchange for, at a360 Media’s option, either (a) $ 860,119 18,547 46.375 1,409,858 12,802 110.125 31,349 Compensation-Stock Compensation Common Stock Reserved for Future Issuance Common stock reserved for future issuance is as follows in common equivalent shares as of June 30, 2023: Summary of Common Stock Reserved for Future Issuance Common stock issuable upon the exercise of stock options outstanding 4,268 Common stock issuable upon the exercise of common stock warrants 3,642,343 Common stock available for future issuance under the 2019 ESPP 509 Common stock available for future issuance under the Amended and Restated 2014 Plan 5,276 Common stock available for future issuance under the Amended Inducement Plan 601 Common stock reserved for the exercise of purchase rights 28,783,233 Common stock reserved for the conversion of convertible notes 158,575,812 Total common stock reserved for future issuance 191,012,042

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	9. Stock-based Compensation Equity Incentive Plans The following table summarizes stock-based compensation expense related to stock options, restricted stock awards (RSAs) granted to employees, non-employee directors and consultants, and the 2019 Employee Stock Purchase Plan (the 2019 ESPP) included in the condensed consolidated statements of operations as follows (in thousands): Schedule of Stock-based Compensation Expense Related to Stock Options 2023 2022 2023 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development 29 166 69 341 Selling and marketing 47 152 104 315 General and administrative 192 763 512 1,492 Total $ 268 $ 1,081 $ 685 $ 2,148 Stock Options There were no 1.6 2.1 Restricted Stock Awards There were no For the performance-based RSAs, (i) the fair value of the award is determined on the grant date; (ii) the Company assesses the probability of achieving each individual milestone associated with the award using reasonable assumptions based on the Company’s operation performance towards each milestone; (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met; and (iv) the Company reassesses the probability of achieving each individual milestone at each reporting date, and any change in estimate is accounted for through a cumulative adjustment in the period when the change in estimate occurs. The non-performance based RSAs are valued at the fair value on the grant date and the associated expenses will be recognized over the vesting period. As of June 30, 2023, there was no Employee Stock Purchase Plan The purchase price under the 2019 ESPP is 85 25,000 There were no shares of common stock purchased under the 2019 ESPP during the three and six months ended June 30, 2023 while there were 601 shares purchased during the three and six months ended June 30, 2022. The fair market value of shares to be issued to employees under the 2019 ESPP is estimated using a Black-Scholes option-pricing model at the grant date, which requires the use of subjective and complex assumptions, including (i) the expected stock price volatility, (ii) the calculation of the expected term of the award, (iii) the risk-free interest rate and (iv) the expected dividend yield. The following weighted average assumptions were used in the calculation of fair value of shares under the 2019 ESPP at the grant dates for the three and six months ended June 30, 2022 . Schedule of Weighted Average Assumptions Three and Six months ended June 30, 2022 Expected volatility 177.2 % Risk-free interest rate 2.3 % Expected dividend yield 0.0 % Expected term (years) 0.5

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events Subsequent events were evaluated through the filing date of this Quarterly Report, August 14, 2023. Additional Financings In July 2023, the Company entered into a securities purchase agreement with certain investors providing for the sale and issuance of senior subordinate convertible notes (the July 2023 SPA). The July 2023 SPA included (i) convertible promissory notes with aggregate original principal amounts of approximately $ 1.5 million (the July 2023 Notes), and (ii) warrants to purchase 1,200,000 shares of common stock (the July 2023 Warrants and collectively, the July 2023 Offering). The July 2023 Offering closed on July 3, 2023 (the July 2023 Closing), with net proceeds to the Company, after deducting offering expenses, of approximately $ 1.0 million. The July 2023 SPA also included a Registration Rights Agreement that requires the Company to register the common stock underlying the July 2023 Notes and July 2023 Warrants within the timeframes specified therein. In August 2023, the Company entered into a securities purchase agreement with certain investors providing for the sale and issuance of senior subordinate convertible notes (the August 2023 SPA). The August 2023 SPA included (i) convertible promissory notes with aggregate original principal amounts of approximately $ 1.0 799,999 0.5 Settlement of Trade Payables Subsequent to June 30, 2023, the Company settled a portion of its trade payables with several vendors, which resulted in a $ 0.1 Increase to Authorized Shares On August 4, 2023, the Company’s board of directors approved, subject to stockholder approval, and recommended its stockholders approve at the 2023 shareholders’ annual meeting in September 2023, 500,000,000 1,200,000,000 Warrants and Purchase Rights Exercises Subsequent to June 30, 2023, there was the noncash exercise of 1,147,332 388,638 Preferred Stock Transaction On August 7, 2023, the Company filed a Certificate of Designation of Series E-1 Convertible Preferred Stock, par value $ 0.0001 0.40 1.8 1,800

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto. Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the discount rate used in estimating the fair value of the lease right - - Note 3 – Revenue Note 4 – Debt Note 6 – Fair Value of Financial Instruments Note 7 – Commitments and Contingencies Note 9 – Stock-based Compensation
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, the Chief Executive Officer of the Company, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by the Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets. The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held. The Company’s deposits were primarily held in Silicon Valley Bank prior to its closure by regulators, however, the Company was able to regain full access to all its deposits and subsequently moved these to a different financial institution. The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the United States and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers and its past collection experience. Historically, the Company has not experienced any credit losses. As of June 30, 2023 and December 31, 2022, based on the evaluation of these factors, the Company did not record an allowance for doubtful accounts. Phexxi is distributed primarily through three major distributors and a mail-order pharmacy, which receive service fees calculated as a percentage of the gross sales, and fee per units shipped, respectively. These entities are not obligated to purchase any set number of units and distribute Phexxi on demand as orders are received. For the three and six months ended June 30, 2023, the Company’s three largest customers combined made up approximately 81 84 72 71 90 81 Significant Accounting Policies There have been no changes to the significant accounting policies that were described in Note 2 – Summary of Significant Accounting Policies
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of readily available cash in checking accounts and money market funds. Restricted cash consists of cash held in monthly time deposit accounts and letters of credit, which are collateral for the Company’s credit cards and fleet leases, as described in Note 7 – Commitments and Contingencies 0.3 25.0 Note 4 – Debt 0.8 The following table provides a reconciliation of cash, cash equivalents and restricted cash, reported within the condensed consolidated statements of cash flows (in thousands): Schedule of Reconciliation of Cash and Restricted Cash 2023 2022 Six months ended June 30, 2023 2022 Cash and cash equivalents $ - $ 19,885 Restricted cash 636 1,581 Restricted cash included in other noncurrent assets - 800 Total cash, cash equivalents and restricted cash presented in the condensed consolidated statements of cash flows $ 636 $ 22,266
Net Loss Per Share	Net Loss Per Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented. Potentially dilutive securities excluded from the calculation of diluted net loss per share are summarized in the table below. Common shares were calculated for the convertible preferred stock and the convertible debt using the if-converted method. Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share 2023 2022 Six months ended June 30, 2023 2022 Unvested restricted common stock subject to repurchase - 1,205 Common stock to be purchased under the 2019 ESPP - 972 Options to purchase common stock 4,268 6,857 Warrants to purchase common stock 3,642,343 984,962 Purchase rights to purchase common stock 28,783,233 - Convertible debt 158,575,812 9,969 Total 191,005,656 1,003,965
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In March 2022, the FASB issued ASU No. 2022-02, Financial Instruments - Credit Losses (ASU No. 2022-02). This is an amendment to ASU 2016-13, where it eliminates the accounting guidance for troubled debt restructuring by creditors in Subtopic 310-40, Receivables—Troubled Debt Restructurings by Creditors, while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. ASU No. 2022-02 was effective for the Company beginning January 1, 2023 since the Company adopted ASU 2016-13 on January 1, 2020. The adoption of this new standard did not have a material impact on the Company’s condensed consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of Reconciliation of Cash and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash, reported within the condensed consolidated statements of cash flows (in thousands): Schedule of Reconciliation of Cash and Restricted Cash 2023 2022 Six months ended June 30, 2023 2022 Cash and cash equivalents $ - $ 19,885 Restricted cash 636 1,581 Restricted cash included in other noncurrent assets - 800 Total cash, cash equivalents and restricted cash presented in the condensed consolidated statements of cash flows $ 636 $ 22,266
Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share 2023 2022 Six months ended June 30, 2023 2022 Unvested restricted common stock subject to repurchase - 1,205 Common stock to be purchased under the 2019 ESPP - 972 Options to purchase common stock 4,268 6,857 Warrants to purchase common stock 3,642,343 984,962 Purchase rights to purchase common stock 28,783,233 - Convertible debt 158,575,812 9,969 Total 191,005,656 1,003,965

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Interest Expense	Interest expense for the Adjuvant Notes for the three and six months ended June 30, 2023 and 2022 consisted of the following (in thousands): Schedule of Interest Expense 2023 2022 2023 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Coupon interest $ 507 $ 523 $ 1,004 $ 1,035 Amortization of issuance costs 60 10 128 19 Total $ 567 $ 533 $ 1,132 $ 1,054

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventories	Inventories consist of the following (in thousands) for the period indicated: Schedule of Inventories June 30, 2023 December 31, 2022 As of June 30, 2023 December 31, 2022 Raw Materials $ 740 $ 758 Work in process (1) 1,705 4,142 Finished Goods 1,388 1,748 Total (2) $ 3,833 $ 6,648 (1) The work in process balance represents all production costs incurred for partially completed goods. (2) A portion of the total inventory balance which relates to inventory not expected to be sold within one year from the balance sheet date is included in other noncurrent assets. At June 30, 2023 and December 31, 2022, inventory included in other noncurrent assets was $ 0.2 1.3
Schedule of Prepaid and Other Current Assets	Prepaid and other current assets consist of the following (in thousands): Schedule of Prepaid and Other Current Assets June 30, 2023 December 31, 2022 As of June 30, 2023 December 31, 2022 Insurance $ 1,764 $ 1,387 Selling and marketing related costs - 44 Manufacturing related costs 77 82 Other 667 705 Total $ 2,508 $ 2,218
Schedule of Property and Equipment net	Property and equipment, net, consists of the following (in thousands): Schedule of Property and Equipment net Useful Life June 30, 2023 December 31, 2022 As of Useful Life June 30, 2023 December 31, 2022 Research equipment 5 years $ 653 $ 653 Computer equipment and software 3 years 648 639 Office furniture 5 years - 881 Leasehold improvements 5 years - 3,388 Construction in-process - 1,562 1,568 Property and equipment gross 2,863 7,129 Less: accumulated depreciation (1,195 ) (3,189 ) Total, net $ 1,668 $ 3,940
Schedule of Accrued Expenses	Accrued expenses consist of the following (in thousands): Schedule of Accrued Expenses June 30, 2023 December 31, 2022 As of June 30, 2023 December 31, 2022 Clinical trial related costs $ 2,498 $ 2,574 Selling and marketing related costs 920 674 Other 798 876 Total $ 4,216 $ 4,124

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Schedule of Fair Value of Financial Assets	Schedule of Fair Value of Financial Assets As of June 30, 2023 December 31, 2022 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (level 2) Significant Unobservable Inputs (Level 3) Significant Unobservable Inputs (Level 3) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (level 2) Significant Unobservable Inputs (Level 3) Significant Unobservable Inputs (Level 3) Total Money market funds (1) $ - $ - $ - $ - $ - $ 2,612 $ - $ - $ - $ 2,612 Total assets $ - $ - $ - $ - $ - $ 2,612 $ - $ - $ - $ 2,612 (1) Included as a component of cash and cash equivalents and restricted cash on the accompanying condensed consolidated balance sheet.
Schedule of Fair Value of Financial Liabilities	The following tables summarize the Company’s derivative liabilities as of June 30, 2023 and December 31, 2022 as discussed in Note 8 - Stockholders’ Deficit (in thousands): Schedule of Fair Value of Financial Liabilities Fair Value June 30, 2023 (2) December 31, 2022 (1) Leveling April and June 2020 Baker Warrants $ N/A $ 1 Level 3 May 2022 Public Offering Warrants N/A 303 Level 3 June 2022 Baker Warrants N/A 170 Level 3 December 2022 Warrants N/A 107 Level 3 February and March 2023 Warrants N/A - Level 3 Purchase rights N/A 1,095 Level 3 Total Derivative Liabilities $ - $ 1,676 (1) As of December 31, 2022, all warrants issued by the Company are subject to liability accounting due to potential settlement in cash, an insufficient number of authorized shares and other adjustment mechanics. However, warrants with an exercise price greater than $ 2.50 de minimus (2) Upon the effectuation of the reverse split on May 18, 2023, the Company has sufficient number of authorized shares. As a result, as of June 30, 2023, all derivatives in the table above were marked-to-market with an immaterial amount on May 18, 2023, and then reclassified to equity.
Term Notes, Baker Notes and December 2022 Notes, and February, March and April 2023 Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Schedule of Change in Fair Value of Level 3 Financial Liabilities	The following tables summarize the changes in Level 3 financial liabilities related to Term Notes, Baker Notes and December 2022 Notes, and February, March and April 2023 Notes measured at fair value on a recurring basis for the three and six months ended June 30, 2023 (in thousands). Schedule of Change in Fair Value of Level 3 Financial Liabilities Baker First Closing Notes Baker Second Closing Notes December 2022 Notes February and March 2023 Notes April 2023 Notes Total Balance at March 31, 2023 $ 14,280 $ 9,520 $ 3 $ 4 $ - $ 23,807 Balance at issuance - - - - 1 1 Change in fair value presented in the Condensed Consolidated Statements of Operations - - 153 7 - 160 Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Operations (4,920 ) (3,280 ) (156 ) (11 ) (1 ) (8,368 ) May 2022 exchange transaction Reclassified to equity Balance at June 30, 2023 $ 9,360 $ 6,240 $ - $ - $ - $ 15,600 Baker First Closing Notes Baker Second Closing Notes December 2022 Notes February and March 2023 Notes April 2023 Notes Total Balance at December 31, 2022 $ 23,556 $ 15,704 $ 156 $ - $ - $ 39,416 Balance at issuance - - - 11 1 12 Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Operations (14,196 ) (9,464 ) (156 ) (11 ) (1 ) (23,828 ) Balance at June 30, 2023 $ 9,360 $ 6,240 $ - $ - $ - $ 15,600 The following tables summarize the changes in Level 3 financial liabilities related to the January 2022 Notes, the March 2022 Notes, the May 2022 Notes, and the Baker Notes measured at fair value on a recurring basis for the three and six months ended June 30, 2022 (in thousands): Term Notes - January 2022 Notes Term Notes - March 2022 Notes Term Notes - May 2022 Notes Term Notes Total Baker First Closing Notes Baker Second Closing Notes Baker Notes Total Balance at March 31, 2022 $ 118 $ 149 $ - $ 267 $ 51,653 $ 34,436 $ 86,089 Balance at issuance - - 447 447 - - - Debt repayment - - (5,892 ) (5,892 ) - - - Change in fair value presented in the Condensed Consolidated Statements of Operations 2 2 9,499 9,503 (1,543 ) (1,029 ) (2,572 ) Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Operations - - - - 2,205 1,470 3,675 May 2022 exchange transaction (120 ) (151 ) - (271 ) - - - Balance at June 30, 2022 $ - $ - $ 4,054 $ 4,054 $ 52,315 $ 34,877 $ 87,192 Term Notes - January 2022 Notes Term Notes - March 2022 Notes Term Notes - May 2022 Notes Term Notes Total Baker First Closing Notes Baker Second Closing Notes Baker Notes Total Balance at December 31, 2021 $ - $ - $ - $ - $ 49,030 $ 32,687 $ 81,717 Balance at issuance 116 149 447 712 — — - Debt repayment — — (5,892 ) (5,892 ) — — - Change in fair value presented in the Condensed Consolidated Statements of Operations 4 2 9,499 9,505 1,189 792 1,981 Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Operations — — — - 2,096 1,398 3,494 May 2022 exchange transaction (120 ) (151 ) — (271 ) — — - Balance at June 30, 2022 $ - $ - $ 4,054 $ 4,054 $ 52,315 $ 34,877 $ 87,192 The following tables summarize the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three and six months ended June 30, 2023 (in thousands): May 2022 Public Offering Common Warrants June December 2022 Warrants February and March 2023 Warrants Purchase Rights Derivative Liabilities Total Balance at March 31, 2023 $ 6 $ 3 $ 1 $ 6 $ 106 $ 122 Balance at issuance - - - - 26 26 Exercises (1 ) - - - (6 ) (7 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (4 ) (2 ) (1 ) (4 ) (73 ) (84 ) Reclassified to equity (1 ) (1 ) - (2 ) (53 ) (57 ) Balance at June 30, 2023 $ - $ - $ - $ - $ - $ - April and June 2020 Baker Warrants May 2022 Public Offering Common Warrants June December 2022 Warrants February and March 2023 Warrants Purchase Rights Derivative Liabilities Total Balance at December 31, 2022 $ 1 $ 303 $ 170 $ 107 $ - $ 1,095 $ 1,676 Balance at issuance - - - - 6 105 111 Exercises - (7 ) - - - (186 ) (193 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (1 ) (295 ) (169 ) (107 ) (6 ) (961 ) (1,539 ) Reclassified to equity - (1 ) (1 ) - - (53 ) (55 ) Balance at June 30, 2023 $ - $ - $ - $ - $ - $ - $ - The following tables summarize the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three and six months ended June 30, 2022 (in thousands): Derivative Liability - Convertible Preferred Stock Conversion Feature Derivative Liability - January 2022 Warrants Derivative Liability - March 2022 Warrants Derivative Liability - May 2022 Warrants May 2022 Public Offering Common Warrants May 2022 Public Offering Pre-Funded Warrants June 2022 Baker Warrants Derivative Liabilities Total Balance at March 31, 2022 $ 92 $ 3,857 $ 3,893 $ - $ - $ - $ - $ 7,842 Balance at issuance - - - 1,613 18,034 4,633 70,238 94,518 Warrant exercises - - - - (7,145 ) (4,633 ) - (11,778 ) Change in fair value presented in the Condensed Consolidated Statements of Operations - (3,168 ) (3,210 ) (926 ) 30,352 - - 23,048 Conversion of series B-2 convertible preferred stock (19 ) - - - - - - (19 ) May 2022 exchange transaction (73 ) - - - - - - (73 ) Balance at June 30, 2022 $ - $ 689 $ 683 $ 687 $ 41,241 $ - $ 70,238 $ 113,538 Derivative Liability - Convertible Preferred Stock Conversion Feature Derivative Liability - January 2022 Warrants Derivative Liability - March 2022 Warrants Derivative Liability - May 2022 Warrants May 2022 Public Offering Common Warrants May 2022 Public Offering Pre-Funded Warrants June 2022 Baker Warrants Derivative Liabilities Total Balance at December 31, 2021 $ 202 $ - $ - $ - $ - $ - $ - $ 202 Balance at issuance - 4,562 6,025 1,613 18,034 4,633 70,238 105,105 Warrant exercises - - - - (7,145 ) (4,633 ) - (11,778 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (83 ) (3,873 ) (5,342 ) (926 ) 30,352 - - 20,128 Conversion of series B-2 convertible preferred stock (46 ) - - - - - - (46 ) May 2022 exchange transaction (73 ) - - - - - - (73 ) Balance at June 30, 2022 $ - $ 689 $ 683 $ 687 $ 41,241 $ - $ 70,238 $ 113,538
Convertible Debt [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Schedule of Fair Value of Financial Liabilities	The following tables summarize the Company’s convertible debt instruments as of June 30, 2023 and December 31, 2022, respectively (in thousands): Schedule of Fair Value of Financial Liabilities Fair Value As of June 30, 2023 Principal Amount Unamortized Issuance Costs Accrued Interest Net Carrying Amount Amount Leveling Baker Notes (1)(2) $ 95,677 $ - $ - $ 95,677 $ 15,600 Level 3 Adjuvant Notes (3)(4) 22,500 (123 ) 5,023 27,400 - N/A December 2022 Notes (1) 2,391 - - 2,391 - Level 3 February and March 2023 Notes (1) 2,590 - - 2,590 - Level 3 April 2023 Notes (1) 784 - - 784 - Level 3 Fair Value As of December 31, 2022 Principal Amount Unamortized Issuance Costs Accrued Interest Redemption Amount Amount Exchanged Net Carrying Amount Amount Leveling Baker Notes (1)(2) $ 45,528 $ - $ - $ - $ - $ 45,528 $ 39,260 Level 3 Adjuvant Notes (3)(4) 22,500 (252 ) 4,020 - - 26,268 - N/A May 2022 Notes (1) 16,376 - 1,101 4,369 (21,846 ) - - N/A December 2022 Notes (1) 2,308 - - - - 2,308 156 Level 3 (1) These liabilities are/were carried at fair value in the condensed consolidated balance sheets. As such, the principal and accrued interest was included in the determination of fair value. The related debt issuance costs were expensed. (2) The Baker Notes principal amount includes $ 9.5 5.6 (3) The Adjuvant Notes are recorded in the condensed consolidated balance sheets at their net carrying amount which includes principal and accrued interest, net of unamortized issuance costs. (4) The principal amount and accrued interest of the Adjuvant Notes are net of the 10 2.5 0.4

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Lease Cost	Schedule of Lease Cost Three Months Ended June 30, Six Months Ended June 30, Lease Cost (in thousands) Classification 2023 2022 2023 2022 Operating lease expense Research and development $ 59 $ 85 $ 125 $ 171 Operating lease expense Selling and marketing 88 268 247 499 Operating lease expense General and administrative 103 250 334 509 Total $ 250 $ 603 $ 706 $ 1,179
Schedule of Lease Term and Discount Rate	Schedule of Lease Term and Discount Rate Lease Term and Discount Rate June 30, 2023 December 31, 2022 Weighted Average Remaining Lease Term (in years) 1.17 2.68 Weighted Average Discount Rate 12 % 12 %
Schedule of Operating Lease Maturities	Schedule of Operating Lease Maturities Maturity of Operating Lease Liabilities (in thousands) June 30, 2023 Remainder of 2023 (6 months) $ 94 Year ending December 31, 2024 109 Year ending December 31, 2025 9 Total lease payments 212 Less imputed interest (17 ) Total $ 195
Schedule of Supplement Cash Outflows in Operating Leases	Schedule of Supplement Cash Outflows in Operating Leases Other information (in thousands) 2023 2022 Six Months Ended June 30, Other information (in thousands) 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows in operating leases $ 1,427 $ 1,289

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Schedule of Warrants	Schedule of Warrants Type of Warrants Underlying Common Stock to be Purchased Exercise Price Issue Date Exercise Period Common Warrants 4 $ 6,918.75 June 11, 2014 June 11, 2014 to June 11, 2024 Common Warrants 452 $ 14,062.50 May 24, 2018 May 24, 2018 to May 24 2025 Common Warrants - $ 14,062.50 June 26, 2018 June 26, 2018 to June 26, 2025 Common Warrants 888 $ 11,962.50 April 11, 2019 October 11, 2019 to April 11, 2026 Common Warrants 1,480 $ 11,962.50 June 10, 2019 December 10, 2019 to June 10, 2026 Common Warrants 1,639 $ 0.8125 April 24, 2020 April 24, 2020 to April 24, 2025 Common Warrants 1,092 $ 0.8125 June 9, 2020 June 9, 2020 to June 9, 2025 Common Warrants 8,003 $ 735.00 January 13, 2022 March 1, 2022 to March 1, 2027 Common Warrants 8,303 $ 897.56 March 1, 2022 March 1, 2022 to March 1, 2027 Common Warrants 6,666 $ 309.56 May 4, 2022 May 4, 2022 to May 4, 2027 Common Warrants 894,194 $ 0.8125 May 24, 2022 May 24, 2022 to May 24, 2027 Common Warrants 582,886 $ 0.8125 June 28, 2022 May 24, 2022 to June 28, 2027 Common Warrants 369,230 $ 0.8125 December 21, 2022 December 21, 2022 to December 21, 2027 Common Warrants 653,538 $ 0.8125 February 17, 2023 February 17, 2023 to February 17, 2028 Common Warrants 240,000 $ 0.8125 March 13, 2023 March 13, 2023 to March 13, 2028 Common Warrants 258,584 $ 0.8125 March 20, 2023 March 20, 2023 to March 20, 2028 Common Warrants 615,384 $ 1.25 April 5, 2023 April 5, 2023 to April 5, 2028 Total 3,642,343
Summary of Common Stock Reserved for Future Issuance	Common stock reserved for future issuance is as follows in common equivalent shares as of June 30, 2023: Summary of Common Stock Reserved for Future Issuance Common stock issuable upon the exercise of stock options outstanding 4,268 Common stock issuable upon the exercise of common stock warrants 3,642,343 Common stock available for future issuance under the 2019 ESPP 509 Common stock available for future issuance under the Amended and Restated 2014 Plan 5,276 Common stock available for future issuance under the Amended Inducement Plan 601 Common stock reserved for the exercise of purchase rights 28,783,233 Common stock reserved for the conversion of convertible notes 158,575,812 Total common stock reserved for future issuance 191,012,042

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense Related to Stock Options	The following table summarizes stock-based compensation expense related to stock options, restricted stock awards (RSAs) granted to employees, non-employee directors and consultants, and the 2019 Employee Stock Purchase Plan (the 2019 ESPP) included in the condensed consolidated statements of operations as follows (in thousands): Schedule of Stock-based Compensation Expense Related to Stock Options 2023 2022 2023 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development 29 166 69 341 Selling and marketing 47 152 104 315 General and administrative 192 763 512 1,492 Total $ 268 $ 1,081 $ 685 $ 2,148
Schedule of Weighted Average Assumptions	Schedule of Weighted Average Assumptions Three and Six months ended June 30, 2022 Expected volatility 177.2 % Risk-free interest rate 2.3 % Expected dividend yield 0.0 % Expected term (years) 0.5

Description of Business and B_2

Description of Business and Basis of Presentation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 15, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 20, 2022	Oct. 03, 2022
Product Information [Line Items]
Revenue		$ 2,458	$ 6,034	$ 8,267	$ 10,285
Reverse stock split description	a reverse stock split between 1-for-20 and not more than 1-for-125 at any time on or prior to March 15, 2024. The Company determined on a ratio of 1-for-125 for the Reverse Stock Split. On May 18, 2023, the Reverse Stock Split became effective.
Proceeds from issuance of debt				2,138	$ 10,000
Cash equivalents and restricted cash		600		600
Working capital		57,700		57,700
Accumulated deficit		$ 949,606		$ 949,606		$ 938,694
Share price								$ 0.01
Common stock, par or stated value per share		$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001	$ 0.01
Debt instrument, restrictive covenants, cumulative net sales requirement				$ 100,000
Phexxi [Member]
Product Information [Line Items]
Revenue						$ 16,800

Schedule of Reconciliation of C

Schedule of Reconciliation of Cash and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash and cash equivalents		$ 2,769	$ 19,885
Restricted cash	636	1,207	1,581
Restricted cash included in other noncurrent assets			800
Total cash, cash equivalents and restricted cash presented in the condensed consolidated statements of cash flows	$ 636	$ 4,776	$ 22,266	$ 13,588

Schedule of Potentially Dilutiv

Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	191,005,656	1,003,965
Unvested Restricted Stock Awards Subject To Repurchase [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		1,205
Employee Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		972
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,268	6,857
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,642,343	984,962
Rights [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	28,783,233
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	158,575,812	9,969

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022	Jun. 30, 2023 USD ($) Integer	Jun. 30, 2022	Dec. 31, 2022	Apr. 14, 2020 USD ($)	Oct. 03, 2019 USD ($)
Product Information [Line Items]
Number of operating segments | Integer			1
Proceeds from convertible debt			$ 25,000
Letter of Credit [Member]
Product Information [Line Items]
Security deposit						$ 50	$ 750
Letter of Credit [Member] | Building and Building Improvements [Member]
Product Information [Line Items]
Security deposit	$ 300		300
Notice of default increase decrease in restricted cash			$ 800
Revenue Benchmark [Member] | Three Largest Customers Combined [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percent	81%	72%	84%	71%
Accounts Receivable [Member] | Three Largest Customers Combined [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percent			90%		81%

Revenue (Details Narrative)

Revenue (Details Narrative) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Trade Accounts Receivable [Member]
Accrued balance of variable considerations		$ 0.1
Other Current Liabilities [Member]
Accrued balance of variable considerations	$ 3.1	$ 2.6
Minimum [Member]
Payment term	31 days
Maximum [Member]
Payment term	66 days

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Debt Disclosure [Abstract]
Coupon interest	$ 507	$ 523	$ 1,004	$ 1,035
Amortization of issuance costs	60	10	128	19
Total	$ 567	$ 533	$ 1,132	$ 1,054

Debt (Details Narrative)

Debt (Details Narrative)

1 Months Ended

3 Months Ended

6 Months Ended

Aug. 31, 2023 USD ($) $ / shares shares

Apr. 30, 2023 USD ($) $ / shares

Mar. 20, 2023 USD ($) shares

Mar. 13, 2023 USD ($) shares

Mar. 07, 2023 USD ($) Integer

Feb. 17, 2023 USD ($) shares

Dec. 21, 2022 USD ($)

Dec. 19, 2022 USD ($)

Sep. 15, 2022 USD ($) $ / shares

Sep. 15, 2022 USD ($) $ / shares shares

May 04, 2022 USD ($) $ / shares shares

Apr. 04, 2022 USD ($) $ / shares

Mar. 21, 2022 USD ($) $ / shares

Feb. 15, 2022

Oct. 14, 2020 USD ($) $ / shares

Jun. 09, 2020 USD ($) $ / shares shares

Apr. 26, 2020

Apr. 24, 2020 USD ($) $ / shares shares

Aug. 14, 2023 shares

May 31, 2023 USD ($)

May 31, 2022 Integer

Jun. 30, 2023 USD ($) $ / shares

Jun. 30, 2022 USD ($)

Mar. 31, 2022 USD ($)

Jun. 30, 2023 USD ($) $ / shares shares

Jun. 30, 2022 USD ($)

Aug. 07, 2023 $ / shares

Jul. 31, 2023 shares

Apr. 05, 2023 $ / shares

Mar. 31, 2023 $ / shares

Feb. 28, 2023 $ / shares

Dec. 31, 2022 USD ($) $ / shares

Dec. 20, 2022 USD ($) $ / shares shares

Oct. 03, 2022 $ / shares

Sep. 30, 2022 $ / shares

Sep. 12, 2022 USD ($)

Apr. 30, 2022 $ / shares

Mar. 01, 2022 USD ($) $ / shares shares

Jan. 13, 2022 USD ($) $ / shares shares

Jan. 02, 2022

Nov. 20, 2021 USD ($) $ / shares shares

Apr. 23, 2020 USD ($)

Debt Instrument [Line Items]

Purchase agreement, threshold amount of aggregate gross proceeds from future sale of equity securities

$ 50,000,000

Interest expense

$ 1,134,000

$ 1,055,000

Debt covenant, cumulative net sales requirement

100,000,000

Debt Instrument, Periodic Payment

$ 92,700,000

Debt Instrument, Convertible, Threshold Trading Days | Integer

3

Convertible notes payable, current

$ 15,600,000

$ 15,600,000

$ 39,416,000

Common stock, par value (in usd per share) | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.01

Net proceeds from offering

$ 300,000

$ 400,000

$ 900,000

Series B-2 Convertible Preferred Stock [Member]

Debt Instrument [Line Items]

Exchange agreement, number of convertible shares to be redeemed (in shares) | shares

2,100

Series C Convertible Preferred Stock [Member]

Debt Instrument [Line Items]

Exchange agreement, number of convertible shares to be redeemed (in shares) | shares

1,700

Common Stock [Member]

Debt Instrument [Line Items]

Conversion price (in usd per share) | $ / shares

$ 587.50

Subsequent Event [Member]

Debt Instrument [Line Items]

Aggregate principal amount of convertible senior secured promissory notes (up to)

$ 1,000,000

[custom:DebtConversionConvertedInstrumentAmount] | shares

1,147,332

Net proceeds from offering

$ 500,000

Minimum [Member]

Debt Instrument [Line Items]

Beneficial ownership limitation percentage

4.99%

Maximum [Member]

Debt Instrument [Line Items]

Beneficial ownership limitation percentage

19.99%

Second Baker Amendment [Member]

Debt Instrument [Line Items]

Conversion price (in usd per share) | $ / shares

$ 725.81

Debt covenant, cumulative net sales requirement

$ 100,000,000

conversion price percentage

100%

Agreegate gross proceeds

$ 20,000,000

Third Baker Amendment [Member]

Debt Instrument [Line Items]

Conversion price (in usd per share) | $ / shares

$ 26.25

$ 26.25

Accrued interest

$ 1,400,000

Debt principal amount

$ 44,200,000

Debt interest payments

$ 1,400,000

Secured Creditor Forbearance Agreement [Member]

Debt Instrument [Line Items]

Debt default amount

$ 1,000,000

Debt instrument indebtedness amount

$ 5,000,000

June 2022 Baker Warrants [Member]

Debt Instrument [Line Items]

Number of shares of to purchase capital stock (in shares) | shares

582,886

Stock option warrant to purchase, exercise price per share (in usd per share) | $ / shares

$ 93.75

Baker Warrants [Member]

Debt Instrument [Line Items]

Stock option warrant to purchase, exercise price per share (in usd per share) | $ / shares

$ 0.8125

$ 1.625

Baker Warrants [Member] | Subsequent Event [Member]

Debt Instrument [Line Items]

Stock option warrant to purchase, exercise price per share (in usd per share) | $ / shares

$ 0.40

Baker Warrants [Member] | Second Baker Amendment [Member]

Debt Instrument [Line Items]

Stock option warrant to purchase, exercise price per share (in usd per share) | $ / shares

$ 93.75

Warrant [Member] | Subsequent Event [Member]

Debt Instrument [Line Items]

Number of shares of to purchase capital stock (in shares) | shares

799,999

1,200,000

December 2022 Warrants [Member]

Debt Instrument [Line Items]

Number of shares of to purchase capital stock (in shares) | shares

369,230

Strike price (in usd per share) | $ / shares

$ 0.8125

$ 1.625

$ 6.25

December 2022 Warrants [Member] | Series D Preferred Stock [Member]

Debt Instrument [Line Items]

Number of shares of to purchase capital stock (in shares) | shares

70

December 2022 Warrants [Member] | Subsequent Event [Member] | Preferred Stock [Member]

Debt Instrument [Line Items]

Debt instrument convertible conversion price | $ / shares

$ 0.40

2023 Warrants [Member]

Debt Instrument [Line Items]

Number of shares of to purchase capital stock (in shares) | shares

215,384

240,000

553,846

2023 Warrants [Member] | Placement Agent [Member]

Debt Instrument [Line Items]

Number of shares of to purchase capital stock (in shares) | shares

43,200

99,692

Baker First Closing Notes [Member] | First Closing Warrants [Member]

Debt Instrument [Line Items]

Number of shares of to purchase capital stock (in shares) | shares

1,639

Unsecured Debt [Member]

Debt Instrument [Line Items]

Warrants and rights outstanding, term

5 years

5 years

Unsecured Debt [Member] | January 2022 Warrants [Member]

Debt Instrument [Line Items]

Stock option warrant to purchase, exercise price per share (in usd per share) | $ / shares

$ 735

Unsecured Debt [Member] | January 2022 Warrants [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Number of shares of to purchase capital stock (in shares) | shares

8,003

Common stock, par value (in usd per share) | $ / shares

$ 0.0001

Unsecured Debt [Member] | March 2022 Warrants [Member]

Debt Instrument [Line Items]

Number of shares of to purchase capital stock (in shares) | shares

8,303

Stock option warrant to purchase, exercise price per share (in usd per share) | $ / shares

$ 897.56

Common stock, par value (in usd per share) | $ / shares

$ 0.0001

May 2022 Notes [Member]

Debt Instrument [Line Items]

Exchange agreement, number of common shares to be redeemed (in shares) | shares

4,266

Exchange agreement, number of common shares to be issued (in shares) | shares

1,666

Debt instrument, redemption price, percentage

100%

Debt instrument, underwritten public offering threshold amount

$ 20,000,000

Debt instrument, underwritten public offering threshold amount

$ 5,900,000

Trading period suspension | Integer

5

Debt default interest rate

18%

Debt default redemption percentage

125%

May 2022 Notes [Member] | Series B-2 Convertible Preferred Stock [Member]

Debt Instrument [Line Items]

Exchange agreement, number of convertible shares to be redeemed (in shares) | shares

2,100

May 2022 Notes [Member] | Series C Convertible Preferred Stock [Member]

Debt Instrument [Line Items]

Exchange agreement, number of convertible shares to be redeemed (in shares) | shares

1,700

May 2022 Notes [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Exchange agreement, number of common shares to be redeemed (in shares) | shares

4,266

May 2022 Notes [Member] | Warrant [Member]

Debt Instrument [Line Items]

Number of shares of to purchase capital stock (in shares) | shares

6,666

Stock option warrant to purchase, exercise price per share (in usd per share) | $ / shares

$ 309.56

Warrants and rights outstanding, term

5 years

Senior Subordinated Notes [Member]

Debt Instrument [Line Items]

Net proceeds from offering

$ 500,000

Senior Subordinated Notes [Member] | April 2023 Warrants [Member]

Debt Instrument [Line Items]

Number of shares of to purchase capital stock (in shares) | shares

615,384

Baker Bros. Notes [Member]

Debt Instrument [Line Items]

Class of warrant or right, vesting term

5 years

Debt instrument, term

2 years

Conversion price (in usd per share) | $ / shares

$ 0.8125

$ 4,575

Conversion price as a percentage of lowest stock price

115%

Debt covenant, cumulative net sales requirement

$ 100,000,000

conversion price percentage

100%

Changes in fair value

$ 8,200,000

8,200,000

Convertible notes payable, current

15,600,000

15,600,000

Convertible notes payable, current, outstanding balance, principal and interest

95,700,000

95,700,000

Baker Bros. Notes [Member] | Subsequent Event [Member]

Debt Instrument [Line Items]

Debt instrument convertible conversion price | $ / shares

$ 0.40

Baker Bros. Notes [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Aggregate principal amount of convertible senior secured promissory notes (up to)

$ 25,000,000

Debt instrument, term

5 years

Debt instrument, term with no prepayment

3 years

Note interest rate percent

10%

Debt conversion, converted instrument, rate

10%

Interest expense

2,400,000

$ 700,000

3,800,000

$ 1,400,000

Debt instrument, convertible, number of shares issuable if converted

$ 117,756,776

$ 117,756,776

Written notice period

10 days

Debt instrument, convertible, weighted average price measurement period

30 days

Debt instrument, convertible, weighted average price measurement period | $ / shares

$ 9,356.25

Conversion price (in usd per share) | $ / shares

$ 4,575

Baker Bros. Notes [Member] | Convertible Notes Payable [Member] | Debt Instrument, Redemption, Period Two [Member]

Debt Instrument [Line Items]

Debt instrument, redemption price, percentage

100%

Baker Bros. Notes [Member] | Convertible Notes Payable [Member] | Debt Instrument, Redemption, Period One [Member]

Debt Instrument [Line Items]

Debt instrument, redemption price, percentage

110%

Baker Bros. Notes [Member] | Convertible Notes Payable [Member] | Debt Instrument, Redemption, Period Three [Member]

Debt Instrument [Line Items]

Debt instrument, redemption price, percentage

110%

Baker Bros. Notes [Member] | Baker First Closing Notes [Member]

Debt Instrument [Line Items]

Securities sold under purchase agreement

$ 15,000,000

Purchase agreement, maximum amount of securities purchasable under agreement

10,000,000

Purchase agreement, threshold amount of aggregate gross proceeds from future sale of equity securities

$ 100,000,000

Baker Bros. Notes [Member] | Baker Second Closing Notes [Member]

Debt Instrument [Line Items]

Securities sold under purchase agreement

$ 10,000,000

Number of shares of to purchase capital stock (in shares) | shares

1,092

Stock option warrant to purchase, exercise price per share (in usd per share) | $ / shares

$ 4,575

February 2023 [Member] | June 2022 Baker Warrants [Member]

Debt Instrument [Line Items]

Stock option warrant to purchase, exercise price per share (in usd per share) | $ / shares

$ 1.625

March 2023 [Member] | June 2022 Baker Warrants [Member]

Debt Instrument [Line Items]

Stock option warrant to purchase, exercise price per share (in usd per share) | $ / shares

0.8125

April 2023 [Member] | June 2022 Baker Warrants [Member]

Debt Instrument [Line Items]

Stock option warrant to purchase, exercise price per share (in usd per share) | $ / shares

$ 0.40

Adjuvant Notes [Member]

Debt Instrument [Line Items]

Debt conversion, converted instrument, rate

7.70%

Conversion price (in usd per share) | $ / shares

$ 678.49

$ 0.8125

$ 0.8125

Conversion price as a percentage of lowest stock price

100%

Debt instrument convertible (in shares) | shares

33,723,393

Adjuvant Notes [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Aggregate principal amount of convertible senior secured promissory notes (up to)

$ 25,000,000

Debt instrument, term

5 years

Note interest rate percent

7.50%

Conversion price (in usd per share) | $ / shares

$ 26.25

$ 26.25

$ 6,843.75

$ 1.625

Debt covenant, cumulative net sales requirement

$ 100,000,000

$ 100,000,000

Common stock, par value (in usd per share) | $ / shares

$ 0.0001

Debt instrument weighted average period

30 days

30 days

Debt instrument weighted average price per share | $ / shares

$ 18,750

$ 18,750

Cumulative adjustment period

2 years

Convertible exchange percentage

10%

10%

Debt Conversion, Converted Instrument, Amount

$ 2,900,000

[custom:DebtConversionConvertedInstrumentAmount] | shares

109,842

Debt instrument convertible conversion price | $ / shares

$ 0.8125

Restricted Cash

$ 25,000,000

$ 25,000,000

$ 600,000

600,000

$ 900,000

Gain (Loss) on Extinguishment of Debt

$ 2,500,000

Convertible debt, noncurrent

27,400,000

27,400,000

Convertible debt, noncurrent principal amount

22,400,000

22,400,000

Convertible debt, noncurrent, accrued interest

$ 5,000,000

$ 5,000,000

Adjuvant Notes [Member] | Convertible Notes Payable [Member] | Subsequent Event [Member] | Preferred Stock [Member]

Debt Instrument [Line Items]

Debt instrument convertible conversion price | $ / shares

$ 0.40

Adjuvant Notes [Member] | Convertible Notes Payable [Member] | Minimum [Member]

Debt Instrument [Line Items]

Beneficial ownership limitation percentage

4.99%

Adjuvant Notes [Member] | Convertible Notes Payable [Member] | Maximum [Member]

Debt Instrument [Line Items]

Beneficial ownership limitation percentage

19.99%

A 50 Senior Subordinated Notes Due 2025 Issued January 2022 [Member] | Unsecured Debt [Member]

Debt Instrument [Line Items]

Aggregate principal amount of convertible senior secured promissory notes (up to)

$ 5,900,000

Interest rate (in percent)

5%

Debt discount

$ 900,000

A 50 Senior Subordinated Notes Due 2025 Issued March 2022 [Member] | Unsecured Debt [Member]

Debt Instrument [Line Items]

Aggregate principal amount of convertible senior secured promissory notes (up to)

$ 7,450,000

Interest rate (in percent)

5%

Debt discount

$ 2,450,000

January and March 2022 Notes [Member] | Unsecured Debt [Member]

Debt Instrument [Line Items]

Interest rate (in percent)

5%

Interest rate in event of default

18%

Interest rate in event of default

25%

25%

A 50 Senior Subordinated Notes [Member] | May 2022 Notes [Member]

Debt Instrument [Line Items]

Aggregate principal amount of convertible senior secured promissory notes (up to)

$ 22,300,000

Interest rate (in percent)

5%

May 2022 Notes [Member]

Debt Instrument [Line Items]

Debt instrument convertible (in shares) | shares

832,237

A 80 Senior Subordinated Notes Due 2025 Issued December 2022 [Member]

Debt Instrument [Line Items]

Conversion price (in usd per share) | $ / shares

$ 6.25

A 80 Senior Subordinated Notes Due 2025 Issued December 2022 [Member] | December 2022 Warrants [Member]

Debt Instrument [Line Items]

Net proceeds from offering

$ 1,250,000

A 80 Senior Subordinated Notes Due 2025 Issued December 2022 [Member] | Unsecured Debt [Member]

Debt Instrument [Line Items]

Aggregate principal amount of convertible senior secured promissory notes (up to)

$ 2,300,000

Interest rate (in percent)

8%

Debt discount

$ 800,000

Interest rate in event of default

12%

Interest rate in event of default

32.50%

Two Thousand Twenty Two December Warrants [Member]

Debt Instrument [Line Items]

Gains reclassified to equity

$ 200,000

2023 Notes [Member]

Debt Instrument [Line Items]

Aggregate principal amount of convertible senior secured promissory notes (up to)

$ 500,000

$ 600,000

$ 1,400,000

April 2023 Notes [Member] | Senior Subordinated Notes [Member]

Debt Instrument [Line Items]

Aggregate principal amount of convertible senior secured promissory notes (up to)

$ 800,000

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw Materials		$ 740	$ 758
Work in process	[1]	1,705	4,142
Finished Goods		1,388	1,748
Total	[2]	$ 3,833	6,648
Inventory			$ 1,300	$ 200
[1]The work in process balance represents all production costs incurred for partially completed goods.[2]A portion of the total inventory balance which relates to inventory not expected to be sold within one year from the balance sheet date is included in other noncurrent assets. At June 30, 2023 and December 31, 2022, inventory included in other noncurrent assets was $ 0.2 1.3

Schedule of Prepaid and Other C

Schedule of Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Impairment Effects on Earnings Per Share [Line Items]
Total	$ 2,508	$ 2,218
Insurance [Member]
Impairment Effects on Earnings Per Share [Line Items]
Total	1,764	1,387
Selling and Marketing Related Costs [Member]
Impairment Effects on Earnings Per Share [Line Items]
Total		44
Prepaid Manufacturing Costs [Member]
Impairment Effects on Earnings Per Share [Line Items]
Total	77	82
Other Current Assets [Member]
Impairment Effects on Earnings Per Share [Line Items]
Total	$ 667	$ 705

Schedule of Property and Equipm

Schedule of Property and Equipment net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 2,863	$ 7,129
Less: accumulated depreciation	(1,195)	(3,189)
Total, net	1,668	3,940
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 653	653
Useful life, Leasehold improvements	5 years
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 648	639
Useful life, Leasehold improvements	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross		881
Useful life, Leasehold improvements	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross		3,388
Useful life, Leasehold improvements	5 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 1,562	$ 1,568

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Clinical trial related costs	$ 2,498	$ 2,574
Selling and marketing related costs	920	674
Other	798	876
Total	$ 4,216	$ 4,124

Schedule of Fair Value of Finan

Schedule of Fair Value of Financial Assets (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			$ 2,612
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	[1]		2,612
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			2,612
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	[1]		2,612
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	[1]
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	[1]
[1]Included as a component of cash and cash equivalents and restricted cash on the accompanying condensed consolidated balance sheet.

Schedule of Fair Value of Fin_2

Schedule of Fair Value of Financial Liabilities (Details) - USD ($) $ in Thousands		Jun. 30, 2023		Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities				$ 1,676
Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities			[1]	1,676	[2]
Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member] | April And June 2022 Baker Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	[2]			1
Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member] | May 2022 Public Offering Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	[2]			303
Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member] | June 2022 Baker Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	[2]			170
Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member] | December 2022 Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	[2]			107
Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member] | February And March 2023 Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	[2]
Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member] | Rights [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	[2]			1,095
Baker Bros. Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value amount		8,200
Baker Bros. Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[3],[4]	95,677		45,528
Unamortized Issuance Costs	[3],[4]
Accrued Interest	[3],[4]
Net carrying amount	[3],[4]	95,677		45,528
Fair value amount	[3],[4]	15,600		39,260
Redemption Amount	[3],[4]
Amount Exchanged	[3],[4]
Adjuvant Notes [Member] | Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[5],[6]	22,500		22,500
Unamortized Issuance Costs	[5],[6]	(123)		(252)
Accrued Interest	[5],[6]	5,023		4,020
Redemption Amount	[5],[6]
Amount Exchanged	[5],[6]
Adjuvant Notes [Member] | Convertible Debt [Member] | Reported Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net carrying amount	[5],[6]	27,400		26,268
Adjuvant Notes [Member] | Convertible Debt [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value amount	[5],[6]
December 2022 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[4]	2,391		2,308
Unamortized Issuance Costs	[4]
Accrued Interest	[4]
Net carrying amount	[4]	2,391		2,308
Fair value amount	[4]			156
Redemption Amount	[4]
Amount Exchanged	[4]
February And March 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[4]	2,590
Unamortized Issuance Costs	[4]
Accrued Interest	[4]
Net carrying amount	[4]	2,590
Fair value amount	[4]
April 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[4]	784
Unamortized Issuance Costs	[4]
Accrued Interest	[4]
Net carrying amount	[4]	784
Fair value amount	[4]
May 2022 Notes [Member] | Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[4]			16,376
Unamortized Issuance Costs	[4]
Accrued Interest	[4]			1,101
Redemption Amount	[4]			4,369
Amount Exchanged	[4]			(21,846)
May 2022 Notes [Member] | Convertible Debt [Member] | Reported Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net carrying amount	[4]
May 2022 Notes [Member] | Convertible Debt [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value amount	[4]
[1]Upon the effectuation of the reverse split on May 18, 2023, the Company has sufficient number of authorized shares. As a result, as of June 30, 2023, all derivatives in the table above were marked-to-market with an immaterial amount on May 18, 2023, and then reclassified to equity.[2]As of December 31, 2022, all warrants issued by the Company are subject to liability accounting due to potential settlement in cash, an insufficient number of authorized shares and other adjustment mechanics. However, warrants with an exercise price greater than $ 2.50 de minimus 9.5 5.6 10 2.5 0.4

Schedule of Fair Value of Fin_3

Schedule of Fair Value of Financial Liabilities (Details) (Parenthetical) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Exercise price threshold for out of the money warrants	$ 2.50
Baker Bros. Notes [Member] | Convertible Debt [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Interest paid in kind	$ 9.5	$ 5.6
Adjuvant Notes [Member] | Convertible Debt [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Percent reduction in principal and interest	10%
Notes reduction	$ 2.5
Reduction in interest	$ 0.4

Schedule of Change in Fair Valu

Schedule of Change in Fair Value of Level 3 Financial Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021			$ 303
Change in fair value presented in the Condensed Consolidated Statements of Operations	$ (73)	$ (29,980)	1,539	$ (31,614)
Reclassified to equity	53
Balance at June 30, 2022
Long-Term Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021	23,807	86,089	39,416	81,717
Balance at issuance	1		12
Change in fair value presented in the consolidated statements of operations	160	(2,572)		1,981
Change in fair value presented in the Condensed Consolidated Statements of Operations	(8,368)	3,675	(23,828)	3,494
May 2022 exchange transaction
Balance at June 30, 2022	15,600	87,192	15,600	87,192
Debt repayment
Long-Term Debt [Member] | Bakers First Closing Note [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021	14,280	51,653	23,556	49,030
Balance at issuance
Change in fair value presented in the consolidated statements of operations		(1,543)		1,189
Change in fair value presented in the Condensed Consolidated Statements of Operations	(4,920)	2,205	(14,196)	2,096
May 2022 exchange transaction
Balance at June 30, 2022	9,360	52,315	9,360	52,315
Debt repayment
Long-Term Debt [Member] | Bakers Second Closing Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021	9,520	34,436	15,704	32,687
Balance at issuance
Change in fair value presented in the consolidated statements of operations		(1,029)		792
Change in fair value presented in the Condensed Consolidated Statements of Operations	(3,280)	1,470	(9,464)	1,398
May 2022 exchange transaction
Balance at June 30, 2022	6,240	34,877	6,240	34,877
Debt repayment
Long-Term Debt [Member] | December 2022 Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021	3		156
Balance at issuance
Change in fair value presented in the consolidated statements of operations	153
Change in fair value presented in the Condensed Consolidated Statements of Operations	(156)		(156)
Balance at June 30, 2022
Long-Term Debt [Member] | February And March 2023 Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021	4
Balance at issuance			11
Change in fair value presented in the consolidated statements of operations	7
Change in fair value presented in the Condensed Consolidated Statements of Operations	(11)		(11)
Balance at June 30, 2022
Long-Term Debt [Member] | April 2023 Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021
Balance at issuance	1
Change in fair value presented in the consolidated statements of operations
Change in fair value presented in the Condensed Consolidated Statements of Operations	(1)
Balance at June 30, 2022
Long-Term Debt [Member] | April 2023 Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021
Balance at issuance			1
Change in fair value presented in the Condensed Consolidated Statements of Operations			(1)
Balance at June 30, 2022
Long-Term Debt [Member] | Term Notes January 2022 Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021		118
Balance at issuance
Change in fair value presented in the consolidated statements of operations		2
Change in fair value presented in the Condensed Consolidated Statements of Operations
May 2022 exchange transaction		(120)
Balance at June 30, 2022
Debt repayment
Long-Term Debt [Member] | Term Notes March 2022 Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021		149
Balance at issuance		447
Change in fair value presented in the consolidated statements of operations		9,499
Change in fair value presented in the Condensed Consolidated Statements of Operations
May 2022 exchange transaction
Balance at June 30, 2022		4,054		4,054
Debt repayment		(5,892)
Long-Term Debt [Member] | A 50 Senior Subordinated Notes Due 2025 Issued May 2022 [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021
Balance at issuance				447
Change in fair value presented in the consolidated statements of operations				9,499
Change in fair value presented in the Condensed Consolidated Statements of Operations
May 2022 exchange transaction
Balance at June 30, 2022		4,054		4,054
Debt repayment				(5,892)
Long-Term Debt [Member] | Term Notes Total [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021		267
Balance at issuance		447		712
Change in fair value presented in the consolidated statements of operations		9,503		9,505
Change in fair value presented in the Condensed Consolidated Statements of Operations
May 2022 exchange transaction		(271)		(271)
Balance at June 30, 2022		4,054		4,054
Debt repayment		(5,892)		(5,892)
Long-Term Debt [Member] | A 50 Senior Subordinated Notes Due 2025 Issued March 2022 [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021
Balance at issuance				149
Change in fair value presented in the consolidated statements of operations		2		2
Change in fair value presented in the Condensed Consolidated Statements of Operations
May 2022 exchange transaction		(151)		(151)
Balance at June 30, 2022
Debt repayment
Long-Term Debt [Member] | A 50 Senior Subordinated Notes Due 2025 Issued January 2022 [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021
Balance at issuance				116
Change in fair value presented in the consolidated statements of operations				4
Change in fair value presented in the Condensed Consolidated Statements of Operations
May 2022 exchange transaction				(120)
Balance at June 30, 2022
Debt repayment
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021	122	7,842	1,676	202
Balance at issuance	26	94,518	111	105,105
Change in fair value presented in the Condensed Consolidated Statements of Operations	(84)	23,048	(1,539)	20,128
Reclassified to equity	(57)		(55)
Balance at June 30, 2022		113,538		113,538
Warrant exercises	(7)	(11,778)	(193)	(11,778)
Conversion of series B-2 convertible preferred stock		(19)		(46)
May 2022 exchange transaction		(73)		(73)
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | May 2022 Public Offering Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021	6
Balance at issuance		18,034		18,034
Change in fair value presented in the Condensed Consolidated Statements of Operations	(4)	30,352	(295)	30,352
Reclassified to equity	(1)		(1)
Balance at June 30, 2022		41,241		41,241
Warrant exercises	(1)	(7,145)	(7)	(7,145)
Conversion of series B-2 convertible preferred stock
May 2022 exchange transaction
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | June 2022 Baker Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021	3		170
Balance at issuance		70,238		70,238
Change in fair value presented in the Condensed Consolidated Statements of Operations	(2)		(169)
Reclassified to equity	(1)		(1)
Balance at June 30, 2022		70,238		70,238
Warrant exercises
Conversion of series B-2 convertible preferred stock
May 2022 exchange transaction
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | December 2022 Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021	1		107
Balance at issuance
Change in fair value presented in the Condensed Consolidated Statements of Operations	(1)		(107)
Reclassified to equity
Balance at June 30, 2022
Warrant exercises
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | February And March 2023 Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021	6
Balance at issuance			6
Change in fair value presented in the Condensed Consolidated Statements of Operations	(4)		(6)
Reclassified to equity	(2)
Balance at June 30, 2022
Warrant exercises
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | Rights [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021	106		1,095
Balance at issuance	26		105
Change in fair value presented in the Condensed Consolidated Statements of Operations	(73)		(961)
Reclassified to equity	(53)		(53)
Balance at June 30, 2022
Warrant exercises	(6)		(186)
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Liability Convertible Preferred Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021		92	1	202
Balance at issuance
Change in fair value presented in the Condensed Consolidated Statements of Operations				(83)
Balance at June 30, 2022
Warrant exercises
Conversion of series B-2 convertible preferred stock		(19)		(46)
May 2022 exchange transaction		(73)		(73)
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Liabilities Previously Classified As Equity Instruments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at issuance
Change in fair value presented in the Condensed Consolidated Statements of Operations			(1)
Reclassified to equity
Warrant exercises
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | January 2022 Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021		3,857
Balance at issuance				4,562
Change in fair value presented in the Condensed Consolidated Statements of Operations		(3,168)		(3,873)
Balance at June 30, 2022		689		689
Warrant exercises
Conversion of series B-2 convertible preferred stock
May 2022 exchange transaction
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | March 2022 Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021		3,893
Balance at issuance				6,025
Change in fair value presented in the Condensed Consolidated Statements of Operations		(3,210)		(5,342)
Balance at June 30, 2022		683		683
Warrant exercises
Conversion of series B-2 convertible preferred stock
May 2022 exchange transaction
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | May 2022 Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021
Balance at issuance		1,613		1,613
Change in fair value presented in the Condensed Consolidated Statements of Operations		(926)		(926)
Balance at June 30, 2022		687		687
Warrant exercises
Conversion of series B-2 convertible preferred stock
May 2022 exchange transaction
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | May 2022 Public Offering Pre-Funded Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2021
Balance at issuance		4,633		4,633
Change in fair value presented in the Condensed Consolidated Statements of Operations
Balance at June 30, 2022
Warrant exercises		(4,633)		(4,633)
Conversion of series B-2 convertible preferred stock
May 2022 exchange transaction

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details Narrative) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Revenue from cumulative net sales	$ 100
Baker Bros. Notes [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Revenue from cumulative net sales	$ 100
Baker Bros. Notes [Member] | Measurement Input Royalty Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input	3.5
Baker Bros. Notes [Member] | Measurement Input, Discount Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input	19

Schedule of Lease Cost (Details

Schedule of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Loss Contingencies [Line Items]
Operating lease expense	$ 250	$ 603	$ 706	$ 1,179
Research and Development Expense [Member]
Loss Contingencies [Line Items]
Operating lease expense	59	85	125	171
Selling and Marketing Expense [Member]
Loss Contingencies [Line Items]
Operating lease expense	88	268	247	499
General and Administrative Expense [Member]
Loss Contingencies [Line Items]
Operating lease expense	$ 103	$ 250	$ 334	$ 509

Schedule of Lease Term and Disc

Schedule of Lease Term and Discount Rate (Details)	Jun. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Weighted Average Remaining Lease Term (in years)	1 year 2 months 1 day	2 years 8 months 4 days
Weighted Average Discount Rate	12%	12%

Schedule of Operating Lease Mat

Schedule of Operating Lease Maturities (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2023 (6 months)	$ 94
Year ending December 31, 2024	109
Year ending December 31, 2025	9
Total lease payments	212
Less imputed interest	(17)
Total	$ 195

Schedule of Supplement Cash Out

Schedule of Supplement Cash Outflows in Operating Leases (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Operating cash outflows in operating leases	$ 1,427	$ 1,289

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)			1 Months Ended		3 Months Ended		6 Months Ended
	May 27, 2022 USD ($) ft²	Jan. 01, 2021 USD ($)	Jun. 30, 2023 USD ($)	Sep. 30, 2022	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) Integer	Jun. 30, 2022 USD ($)	Mar. 31, 2023 USD ($)	Mar. 20, 2023 USD ($)	Dec. 31, 2022 USD ($)	Apr. 14, 2020 USD ($) ft²	Dec. 31, 2019	Oct. 03, 2019 USD ($) ft²
Loss Contingencies [Line Items]
Number of leased vehicles | Integer							21
Restricted cash			$ 636,000		$ 636,000	$ 1,581,000	$ 636,000	$ 1,581,000			$ 1,207,000
Square footage | ft²												8,816		24,474
Renewal period														5 years
Operating lease right-of-use assets			195,000		195,000		195,000				4,406,000
Operating lease liabilities			22,000		22,000		22,000				3,133,000
Gain on termination of lease							459,000
Company area (in square feet) | ft²	16,637
Lease expenses	$ 100,000
Lease percentage	3.50%
Sublease gross income							300,000
Purchase obligation, purchases during the period					0	0	0	0
Trade payables			$ 1,300,000		$ 1,300,000		$ 1,300,000
Percentage of trade payables			98%		98%		98%
Accrued expenses			$ 4,216,000		$ 4,216,000		$ 4,216,000				4,124,000
Rush License Agreement [Member]
Loss Contingencies [Line Items]
Royalty cost					200,000	$ 200,000	300,000	$ 500,000
Accrued expenses			700,000		700,000		700,000				600,000
Rush License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty cost		$ 100,000
Rush License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty cost		$ 100,000
Landlord and Terminated 2022 Lease [Member]
Loss Contingencies [Line Items]
Operating lease right-of-use assets			3,300,000		3,300,000		3,300,000
Operating lease liabilities			4,200,000		4,200,000		4,200,000
Gain on termination of lease			200,000
Letter of Credit [Member]
Loss Contingencies [Line Items]
Security deposit												$ 50,000		$ 750,000
Vehicles [Member] | Securities Deposit [Member]
Loss Contingencies [Line Items]
Restricted cash									$ 300,000
Building and Building Improvements [Member] | Letter of Credit [Member]
Loss Contingencies [Line Items]
Restricted cash										$ 800,000
Security deposit			$ 300,000		$ 300,000		$ 300,000
Building and Building Improvements [Member] | Securities Deposit [Member]
Loss Contingencies [Line Items]
Restricted cash											$ 800,000
Lease Contract Term One [Member]
Loss Contingencies [Line Items]
Weighted average remaining lease term (in years)				24 months
Extended lease term				12 months
Lease Contract Term One [Member] | Vehicles [Member]
Loss Contingencies [Line Items]
Weighted average remaining lease term (in years)													24 months
Lease Contract Term [Member] | Vehicles [Member]
Loss Contingencies [Line Items]
Weighted average remaining lease term (in years)													36 months

Schedule of Warrants (Details)

Schedule of Warrants (Details) - $ / shares	Apr. 05, 2023	Mar. 20, 2023	Mar. 13, 2023	Feb. 17, 2023	Dec. 21, 2022	Jun. 28, 2022	May 24, 2022	May 04, 2022	Mar. 01, 2022	Jan. 13, 2022	Jun. 09, 2020	Apr. 24, 2020	Jun. 10, 2019	Apr. 11, 2019	Jun. 26, 2018	May 24, 2018	Jun. 11, 2014	Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of warrant or right outstanding																		3,642,343
Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of warrant or right outstanding	615,384	258,584	240,000	653,538	369,230	582,886	894,194	6,666	8,303	8,003	1,092	1,639	1,480	888		452	4
Exercise price	$ 1.25	$ 0.8125	$ 0.8125	$ 0.8125	$ 0.8125	$ 0.8125	$ 0.8125	$ 309.56	$ 897.56	$ 735	$ 0.8125	$ 0.8125	$ 11,962.50	$ 11,962.50	$ 14,062.50	$ 14,062.50	$ 6,918.75
Warrants exercise period	April 5, 2023 to April 5, 2028	March 20, 2023 to March 20, 2028	March 13, 2023 to March 13, 2028	February 17, 2023 to February 17, 2028	December 21, 2022 to December 21, 2027	May 24, 2022 to June 28, 2027	May 24, 2022 to May 24, 2027	May 4, 2022 to May 4, 2027	March 1, 2022 to March 1, 2027	March 1, 2022 to March 1, 2027	June 9, 2020 to June 9, 2025	April 24, 2020 to April 24, 2025	December 10, 2019 to June 10, 2026	October 11, 2019 to April 11, 2026	June 26, 2018 to June 26, 2025	May 24, 2018 to May 24 2025	June 11, 2014 to June 11, 2024

Summary of Common Stock Reserve

Summary of Common Stock Reserved for Future Issuance (Details) shares in Thousands	Jun. 30, 2023 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved upon exercise of common stock warrants	3,642,343
Common stock reserved for the exercise of purchase rights	28,783,233
Common stock reserved for conversion of convertible notes	158,575,812
Common stock capital shares reserved for future issuance	191,012,042
Inducement Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available for grant	601
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved upon exercise of stock options outstanding	4,268
Share-Based Payment Arrangement, Option [Member] | Employee Stock Purchase Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved for future issuance under employee stock purchase plan	509
Share-Based Payment Arrangement, Option [Member] | Amended and Restated 2014 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available for grant	5,276

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative)

1 Months Ended

3 Months Ended

6 Months Ended

Sep. 15, 2022 Integer

Jul. 18, 2022 USD ($) $ / shares shares

Jun. 08, 2022 USD ($) $ / shares shares

Mar. 31, 2022 $ / shares shares

Mar. 24, 2022 $ / shares shares

Feb. 15, 2022 USD ($) shares

Aug. 14, 2023 shares

Jun. 30, 2022 $ / shares shares

May 31, 2022 USD ($) $ / shares shares

Apr. 30, 2022 $ / shares shares

Oct. 31, 2021 $ / shares shares

Jun. 30, 2023 $ / shares shares

Jun. 30, 2022 USD ($) $ / shares shares

Jun. 30, 2023 USD ($) Integer $ / shares shares

Jun. 30, 2022 USD ($) $ / shares shares

Aug. 07, 2023 $ / shares

Aug. 04, 2023 shares

Apr. 30, 2023 $ / shares

Mar. 31, 2023 $ / shares shares

Dec. 31, 2022 $ / shares shares

Dec. 20, 2022 $ / shares

Dec. 16, 2022 $ / shares shares

Oct. 03, 2022 $ / shares

May 04, 2022 USD ($) shares

Apr. 25, 2022 $ / shares

Jan. 31, 2022 $ / shares shares

Dec. 15, 2021 $ / shares shares

Jun. 30, 2020 $ / shares shares

Apr. 30, 2020 $ / shares shares

Class of Warrant or Right [Line Items]

Total proceeds from warrants exercised | $

$ 160,000

$ 20,922,000

Common stock, par or stated value per share | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.01

Preferred stock, par value | $ / shares

0.0001

0.0001

0.0001

$ 0.0001

Temporary equity, par value | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

Preferred stock, shares authorized

5,000,000

5,000,000

5,000,000

5,000,000

Preferred Stock, Shares Issued

0

0

0

Common stock, shares authorized

500,000,000

500,000,000

500,000,000

500,000,000

Warrants outstanding

3,642,343

3,642,343

a360 Media, LLC [Member]

Class of Warrant or Right [Line Items]

Service agreement cash option | $

$ 1,409,858

$ 860,119

Issued for services

12,802

18,547

Shares issued price per share | $ / shares

$ 110.125

$ 46.375

a360 Media, LLC [Member] | Unregistered Shares [Member]

Class of Warrant or Right [Line Items]

Issued for services

31,349

Adjuvant and May 2022 Notes [Member]

Class of Warrant or Right [Line Items]

Number of outstanding purchase rights | Integer

942,080

15,218,227

Exercises of certain Purchase Rights

673,820

Warrants outstanding

28,783,233

28,783,233

Series B-2 Convertible Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Stock Issued During Period, Shares, Conversion of Convertible Securities

2,347

Temporary equity shares exchange of convertible securities

1,700

Exchange agreement, number of convertible shares to be redeemed

2,100

Series C Convertible Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Temporary equity shares exchange of convertible securities

1,700

Temporary equity, par value | $ / shares

$ 0.0001

Temporary equity stated value per share | $ / shares

$ 1,000

Exchange agreement, number of convertible shares to be redeemed

1,700

Exchange agreement, aggregate principal amount redeemed | $

$ 4,800,000

Exchange agreement, number of warrants to be issued

6,666

Series D Non-Convertible Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Preferred stock, par value | $ / shares

$ 0.0001

Preferred stock, shares authorized

70

Preferred stock voting right power percentage

1%

Preferred Stock, Shares Issued

70

Common Stock [Member]

Class of Warrant or Right [Line Items]

Common stock, par or stated value per share | $ / shares

$ 675

Issued for commitment fee

8,648

Common Stock [Member] | Seven Knots LLC [Member]

Class of Warrant or Right [Line Items]

Stock sale agreement, authorized amount | $

$ 50,000,000

Issued for commitment fee

1,025

Common Stock [Member]

Class of Warrant or Right [Line Items]

Stock Issued During Period, Shares, Conversion of Convertible Securities

1,369

Conversion price per share | $ / shares

$ 587.50

Issued for services

18,547

Minimum [Member]

Class of Warrant or Right [Line Items]

Benefical ownership limitation

4.99%

Maximum [Member]

Class of Warrant or Right [Line Items]

Benefical ownership limitation

19.99%

May 2022 Public Offering [Member]

Class of Warrant or Right [Line Items]

Class of warrant or right, number of securities called by warrants or rights

568,000

Exercise price | $ / shares

$ 93.75

May 2022 Public Offering [Member] | Minimum [Member]

Class of Warrant or Right [Line Items]

Limitations on exercise provisions percentage

4.99%

May 2022 Public Offering [Member] | Maximum [Member]

Class of Warrant or Right [Line Items]

Limitations on exercise provisions percentage

19.99%

Registered Direct Offering [Member] | Series B1 Convertible Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Number of shares issued in transaction

5,000

Preferred stock, par value | $ / shares

$ 0.0001

Sale of stock price per share | $ / shares

$ 1,000

Conversion of Stock, Shares Converted

1,200

5,000

Registered Direct Offering [Member] | Series B-2 Convertible Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Number of shares issued in transaction

5,000

Preferred stock, par value | $ / shares

$ 0.0001

Sale of stock price per share | $ / shares

$ 1,000

Preferred Stock, Redemption Price Per Share | $ / shares

$ 332.50

Public Offering [Member]

Class of Warrant or Right [Line Items]

Number of shares issued in transaction

181,320

Sale of stock price per share | $ / shares

$ 93.75

May 2022 Public Offering Pre-Funded Warrants [Member]

Class of Warrant or Right [Line Items]

Sale of stock price per share | $ / shares

$ 93.63

Subsequent Event [Member]

Class of Warrant or Right [Line Items]

Number of shares issued in transaction

388,638

Common stock, shares authorized

1,200,000,000

Baker Warrants [Member]

Class of Warrant or Right [Line Items]

Exercise price | $ / shares

$ 0.8125

$ 1.625

Baker Warrants [Member] | Subsequent Event [Member]

Class of Warrant or Right [Line Items]

Exercise price | $ / shares

$ 0.40

Prefunded Warrants [Member]

Class of Warrant or Right [Line Items]

Class of warrant or right, number of securities called by warrants or rights

102,680

Exercise price | $ / shares

$ 0.125

Second May 2022 Public Offering Warrants [Member]

Class of Warrant or Right [Line Items]

Warrants and rights outstanding term

5 years

May 2022 Public Offering [Member]

Class of Warrant or Right [Line Items]

Warrants exercised

225,039

225,039

225,039

Total proceeds from warrants exercised | $

$ 21,100,000

June 2022 Baker Warrants [Member]

Class of Warrant or Right [Line Items]

Class of warrant or right, number of securities called by warrants or rights

582,886

582,886

582,886

Exercise price | $ / shares

$ 93.75

$ 93.75

$ 93.75

1.625

Warrants and rights outstanding term

5 years

5 years

5 years

Common stock, par or stated value per share | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

June 2022 Baker Warrants [Member] | Minimum [Member]

Class of Warrant or Right [Line Items]

Benefical ownership limitation

4.99%

June 2022 Baker Warrants [Member] | Maximum [Member]

Class of Warrant or Right [Line Items]

Benefical ownership limitation

19.99%

June 2022 Baker Warrants [Member] | Subsequent Event [Member]

Class of Warrant or Right [Line Items]

Exercise price | $ / shares

0.40

Second May 2022 Public Offering [Member]

Class of Warrant or Right [Line Items]

Exercise price | $ / shares

0.8125

May 2022 Public Offering Warrants [Member]

Class of Warrant or Right [Line Items]

Class of warrant or right, number of securities called by warrants or rights

362,640

Exercise price | $ / shares

$ 93.75

0.8125

Warrants and rights outstanding term

5 years

May 2022 Public Offering Warrants [Member] | Warrant [Member]

Class of Warrant or Right [Line Items]

Exercise price | $ / shares

$ 1.625

May 2022 Public Offering Warrants [Member] | Subsequent Event [Member]

Class of Warrant or Right [Line Items]

Exercise price | $ / shares

0.40

May 2022 Public Offering Pre-Funded Warrants [Member]

Class of Warrant or Right [Line Items]

Class of warrant or right, number of securities called by warrants or rights

205,360

Proceeds from public offering | $

$ 18,100,000

Payments of public offering | $

$ 5,900,000

May 2022 Public Offering Pre-Funded Warrants [Member] | Prefunded Warrants [Member]

Class of Warrant or Right [Line Items]

Class of warrant or right, number of securities called by warrants or rights

102,680

Exercise price | $ / shares

$ 0.125

Baker Bros Purchase Agreement [Member]

Class of Warrant or Right [Line Items]

Class of warrant or right, number of securities called by warrants or rights

2,732

2,732

Exercise price | $ / shares

$ 4,575

$ 4,575

Securities Purchase Agreement [Member]

Class of Warrant or Right [Line Items]

Class of warrant or right, number of securities called by warrants or rights

8,303

8,003

Exercise price | $ / shares

$ 897.56

$ 735

Exchange Agreement [Member]

Class of Warrant or Right [Line Items]

Class of warrant or right, number of securities called by warrants or rights

6,666

Exercise price | $ / shares

$ 309.56

Warrants and rights outstanding term

5 years

Security Purchase Agreement [Member]

Class of Warrant or Right [Line Items]

Class of warrant or right, number of securities called by warrants or rights

3,642,343

3,642,343

1,152,122

Exercise price | $ / shares

$ 14.64

$ 14.64

$ 0.8125

$ 2.50

Security Purchase Agreement [Member] | Common Stock [Member]

Class of Warrant or Right [Line Items]

Exercise price | $ / shares

$ 1.25

Warrants exercised

615,384

Security Purchase Agreement [Member] | Subsequent Event [Member] | Warrant [Member]

Class of Warrant or Right [Line Items]

Exercise price | $ / shares

$ 0.40

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expense Related to Stock Options (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 268	$ 1,081	$ 685	$ 2,148
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	29	166	69	341
Selling and Marketing Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	47	152	104	315
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 192	$ 763	$ 512	$ 1,492

Schedule of Weighted Average As

Schedule of Weighted Average Assumptions (Details) - Employee Stock Purchase Plan 2019 [Member]	6 Months Ended
	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected Volatility	177.20%
Risk-free interest rate	2.30%
Expected dividend yield	0%
Expected term (years)	6 months

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022
Employee Stock Purchase Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans			601
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of stock options granted	0	0
Stock based compensation expense		$ 1,600,000
Weighted-average remaining period		2 years 1 month 6 days
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of performance-based RSAs granted	0	0
Unrecognized noncash stock-based compensation expense	$ 0	$ 0
Employee Stock [Member] | Employee Stock Purchase Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Purchase price of common stock		85%
Maximum stock value available for purchase denominator	$ 25,000	$ 25,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Millions							1 Months Ended
	Aug. 31, 2023	Aug. 07, 2023	Jul. 31, 2023	Mar. 20, 2023	Mar. 13, 2023	Feb. 17, 2023	Aug. 14, 2023	Aug. 04, 2023	Jun. 30, 2023	Dec. 31, 2022	Dec. 15, 2021
Subsequent Event [Line Items]
Net proceeds from offering				$ 0.3	$ 0.4	$ 0.9
Trade payables									$ 1.3
Common stock, shares authorized									500,000,000	500,000,000	500,000,000
Preferred Stock, Par or Stated Value Per Share									$ 0.0001	$ 0.0001	$ 0.0001
Subsequent Event [Member]
Subsequent Event [Line Items]
Convertible Debt			$ 1.5
Aggregate principal amounts	$ 1
Net proceeds from offering	$ 0.5
Trade payables							$ 0.1
Common stock, shares authorized								1,200,000,000
Debt instrument, convertible, number of equity instruments							1,147,332
Number of shares issued in transaction							388,638
Subsequent Event [Member] | Series E1 Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred Stock, Par or Stated Value Per Share		$ 0.0001
Conversion price		$ 0.40
Exchange amount		$ 1.8
Debt Conversion, Converted Instrument, Shares Issued		1,800
Subsequent Event [Member] | July 3, 2023 Closings [Member]
Subsequent Event [Line Items]
Proceeds after deducting offering expenses			$ 1
Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Number of shares to purchase capital stock	799,999		1,200,000